MANAGEMENT OF TUBERCULOSIS

Federal Bureau of Prisons
Clinical Practice Guidelines

OCTOBER 2015

Clinical guidelines are made available to the public for informational purposes only. The Federal Bureau of Prisons (FBOP) does not warrant these guidelines for any other purpose, and assumes no responsibility for any injury or damage resulting from the reliance thereof. Proper medical practice necessitates that all cases are evaluated on an individual basis and that treatment decisions are patient-specific. Consult the FBOP Health Management Resources Web page to determine the date of the most recent update to this document: http://www.bop.gov/resources/health_care_mngmt.jsp
WHAT’S NEW IN THIS DOCUMENT?

Changes made in this 2015 version of the guidelines are listed below.

THE FOLLOWING CLINICAL PEARLS EMPHASIZED

► Diabetes is an increasingly important TB risk factor.
► Negative acid-fast bacilli (AFB) smears from sputum or bronchoscopy DO NOT rule out TB.
► Negative tuberculin skin test (TST) DOES NOT rule out active TB.
► Negative interferon gamma release assay (IGRA) DOES NOT rule out active TB.
► Determination of treatment completion for both latent TB infection (LTBI) and active TB is based upon counted doses ingested, NOT time elapsed.

SCREENING

► If an inmate is in holdover status, and has documentation of a negative TST in the last year while incarcerated, then that TST is considered valid for screening purposes (see Section 3).
► Currently, IGRA®s (QuantIFERON® and T-Spot®) are recommended ONLY when working up a TST negative inmate for active TB or if TST results are questionable. Future use is being evaluated.  
  ➤ See the discussion of IGRA®s in Section 3.
► For HIV-infected, TST positive inmates who refuse LTBI treatment, only those with CD4+ T cell count < 200 cells/mm³ require semi-annual CXRs indefinitely.  
  ➤ See Treatment Refusals in Section 4.

TREATMENT OF LATENT TB INFECTION (LTBI)

► 12-week isoniazid-rifapentine (INH-RPT) is standard BOP LTBI treatment unless contraindicated.  
  ➤ See Appendix 3a and Appendix 3c.
► Medication Look-Alike/Sound-Alike Alert: Do not confuse rifapentine (RPT) with rifampin (RIF) or rifabutin (RBU/RBT).

DIAGNOSIS OF ACTIVE TB DISEASE

► The use of local or state public health lab is recommended for sputum AFB testing.
► Guidance has been updated for evaluating inmates with CXRs with TB activity undetermined.  
  ➤ See Old Healed TB vs. Active TB: A Diagnostic Challenge in Section 5.
► Sputum collection / sputum induction procedures are included.  
  ➤ See Appendix 5.
► Guidance is provided on interpreting nucleic acid amplification test (rapid test) results.  
  ➤ See Table 1
► In general, fluoroquinolones (ciprofloxacin, levofloxacin, moxifloxacin) should be avoided when active TB disease is in the differential diagnosis.  
  ➤ See Section 5 (fluoroquinolones)

TREATMENT OF ACTIVE TB

► Standard treatment for active TB disease is now recommended to be DAILY throughout treatment (no intermittent dosing).
► A detailed checklist for TB case management is provided.  
  ➤ See Appendix 4, TB Case Management Checklist.
**CRITERIA FOR DISCONTINUATION OF ISOLATION**

- Criteria for discontinuation of isolation revised.
  - See Appendix 7 for revised criteria.
- Inmates in airborne infection isolation must be seen by a health care provider daily while isolated, with the visit documented in the medical record.
- Inmates in isolation beyond 14 days will have a case conference weekly until isolation discontinued.

**CONTACT INVESTIGATION**

- Contact Investigation interview form is provided.
  - See Appendix 9.
- Presumptive LTBI treatment for close contacts of infectious TB patients is recommended for patients taking immunosuppressive therapy for organ transplantation or TNF-alpha antagonists regardless of their TST result. (This is in addition to HIV-infected contacts).
  - See Medical Evaluation of Contacts in Section 7.

**TB PROGRAM MANAGEMENT**

- Each suspected/confirmed TB case shall be assigned a TB Case Manager. TB case management responsibilities are listed.
  - See TB Case Management in Section 10
- Each facility shall annually complete a Tuberculosis Exposure Control Plan that defines facility-specific procedures fulfilling BOP policy, OSHA regulatory requirements, and these Clinical Practice Guidelines.
  - See Section 10, TB Exposure Control Plan
# TABLE OF CONTENTS

1. **PURPOSE** .......................................................................................................................... 1

2. **EPIDEMIOLOGY, TRANSMISSION, AND NATURAL HISTORY** ......................................................... 1

3. **SCREENING** ....................................................................................................................... 2
   - Intake TB Symptom Screening ......................................................................................... 2
   - Chest Radiograph Screening .......................................................................................... 2
     - Intake Chest X-Rays (CXRs) ....................................................................................... 2
   - Screening for Latent TB Infection .................................................................................. 3
   - Tuberculin Skin Test (TST) ............................................................................................ 3
     - Indications for Tuberculin Skin Testing ...................................................................... 3
     - Special Considerations Regarding the TST ................................................................. 4
     - Administering and Reading TSTs ............................................................................... 4
     - Interpreting Skin Test Reactions ................................................................................. 5
     - Booster Phenomenon and Two-Step Testing ............................................................... 5
   - Interferon-Gamma Release Assays (IGRAs) .................................................................. 6

4. **LATENT TUBERCULOSIS INFECTION (LTBI)** ............................................................................. 8
   - Baseline Evaluation for LTBI ......................................................................................... 8
   - Indications for Treatment of LTBI .................................................................................. 10
   - Treatment Regimens for LTBI ....................................................................................... 10
   - Special Considerations in Treating LTBI ....................................................................... 11
     - Treatment Refusals .................................................................................................. 11
     - Contraindications to LTBI Treatment ......................................................................... 12
     - HIV Co-Infection ....................................................................................................... 12
     - Pregnancy .................................................................................................................. 12
     - Old Healed TB ........................................................................................................... 13
     - BCG Vaccination ........................................................................................................ 13
     - Contacts to Multiple Drug Resistant TB (MDR-TB) ................................................... 13
     - Anti-TNF Alpha Drugs (Tumor Necrosing Factor Alpha Antagonists) ........................ 13
   - Monitoring LTBI Treatment ............................................................................................ 13
     - Clinician Evaluations ............................................................................................... 13
     - Inmate Counseling .................................................................................................... 13
     - Baseline/Ongoing Laboratory Tests .......................................................................... 13
     - Monitoring Drug Side Effects .................................................................................... 14
     - Interruption or Discontinuation of Treatment ............................................................. 14
     - Documentation of Treatment Regimen ....................................................................... 15
   - Strategies for a Successful LTBI Treatment Program .................................................... 15
5. **DIAGNOSIS OF ACTIVE TUBERCULOSIS DISEASE**

- Diagnostic Issues ........................................................................................................................................... 16
- Medical History and Physical Exam ............................................................................................................... 16
- Chest Radiograph Manifestations of TB .......................................................................................................... 17
- Diagnostic Microbiology ................................................................................................................................. 17
- DNA Fingerprinting ........................................................................................................................................ 19
- Old Healed TB vs. Active TB: A Diagnostic Challenge .................................................................................. 19
- Extrapulmonary TB .......................................................................................................................................... 20
- Reporting Suspected/Confirmed Tuberculosis Cases ...................................................................................... 20

6. **TREATMENT OF TUBERCULOSIS DISEASE** ......................................................................................... 21

- General Principles .......................................................................................................................................... 21
- Standard Tuberculosis Treatment Regimen ..................................................................................................... 22
- Special Situations in Treating Active TB ......................................................................................................... 23
  - Culture-Negative Pulmonary TB .................................................................................................................. 23
  - Extrapulmonary TB ....................................................................................................................................... 23
  - HIV Co-Infection ......................................................................................................................................... 24
- Cavitary TB with Positive Cultures at Two Months ...................................................................................... 25
- Renal insufficiency and End-Stage Renal Disease ....................................................................................... 25
- Drug Resistance and Intolerance .................................................................................................................. 25
- Monitoring Treatment .................................................................................................................................... 26

7. **CONTACT INVESTIGATIONS** ................................................................................................................. 29

- Stepwise Procedure for Contact Investigation ............................................................................................... 29
- Transmission Factors ...................................................................................................................................... 29
- Decision to Initiate a Contact Investigation .................................................................................................. 30
- Prioritizing and Structuring the Contact Investigation .................................................................................. 31
- Medical Evaluation of Contacts ..................................................................................................................... 32

8. **INFECTION CONTROL MEASURES** ....................................................................................................... 33

- Early Detection ................................................................................................................................................ 33
- Airborne Infection Isolation ............................................................................................................................. 33
- Transport .......................................................................................................................................................... 34

9. **DISCHARGE PLANNING** ......................................................................................................................... 35

10. **TB PROGRAM MANAGEMENT** ........................................................................................................... 36

- TB Case Management .................................................................................................................................. 36
- TB Exposure Control Plan .............................................................................................................................. 37
- Program Evaluation ......................................................................................................................................... 37
DEFINITIONS .................................................................................................................................... 38

REFERENCES ...................................................................................................................................... 42

APPENDIX 1. TUBERCULOSIS RISK FACTORS ................................................................................. 45

APPENDIX 2. TUBERCULIN SKIN TESTING GUIDELINES ................................................................. 46

APPENDIX 3A. STANDARD TREATMENT FOR LATENT TB INFECTION ........................................... 47

APPENDIX 3B. ALTERNATIVE REGIMENS FOR TREATMENT OF LATENT TB INFECTION .................. 48

APPENDIX 3C. TREATMENT OF LTBI: BASELINE AND ONGOING MONITORING ............................... 49

APPENDIX 4. TB CASE MANAGEMENT CHECKLIST .......................................................................... 50

APPENDIX 5. SPUTUM COLLECTION / INDUCTION PROCEDURES ................................................ 54

APPENDIX 6A. STANDARD TUBERCULOSIS TREATMENT REGIMEN – 6 MONTHS ......................... 56

APPENDIX 6B. FIRST-LINE TUBERCULOSIS DRUG DOSES ............................................................. 57

APPENDIX 6C. TUBERCULOSIS TREATMENT REGIMENS IN SPECIAL SITUATIONS ......................... 58

APPENDIX 7. CRITERIA FOR DISCONTINUATION OF AIRBORNE INFECTION ISOLATION AND RETURN OF AN INMATE WITH SUSPECTED TB TO GENERAL POPULATION ......................................................... 59

APPENDIX 8. TUBERCULOSIS CONTACT INVESTIGATION – CHECKLIST ........................................ 60

APPENDIX 9. TB CONTACT INVESTIGATION INTERVIEW .............................................................. 62

TABLE:

TABLE 1. INTERPRETATION OF NUCLEIC ACID AMPLIFICATION TEST RESULTS ......................... 18
1. PURPOSE

The Federal Bureau of Prisons Clinical Practice Guidelines for the Management of Tuberculosis provide recommendations for the treatment of federal inmates with tuberculosis (TB) infection and disease and for the management of contacts to infectious TB cases.

2. EPIDEMIOLOGY, TRANSMISSION, AND NATURAL HISTORY

TB incidence in the United States decreased during the past two decades. However, TB prevention and control remains a high public health priority for correctional systems, since TB outbreaks continue to occur in U.S. jails and prisons. Furthermore, a significant proportion of TB cases in the U.S. occur among persons who are over-represented in certain jails or prisons—including racial/ethnic minority populations, persons with human immunodeficiency virus (HIV) infection, and persons born in foreign countries that have high rates of TB. The rate of TB in correctional facilities is four to five times greater than in the U.S. population as a whole.

**TRANSMISSION:** *Mycobacterium tuberculosis*, the organism that causes TB, is transmitted through airborne respiratory droplets when an individual with active pulmonary TB coughs, sneezes, speaks, or sings. Transmission of *M. tuberculosis* depends on the length of time and frequency of the exposure, the degree of contagiousness of the infected person, the environment and airflow in which the exposure occurred, and the intensity of the contact with the TB organism itself. Infection with *M. tuberculosis* usually requires prolonged contact with an infectious case in an enclosed space.

- The majority of persons who become infected never develop active TB.

**RISK FACTORS FOR LATENT TB INFECTION (LTBI):** The most significant risk factor for LTBI is country of origin. The general U.S. population has an estimated TB infection rate of only 5–10%; whereas, foreign-born populations have an average estimated TB infection rate of 32%, with rates varying widely throughout the world. Other risk factors for infection with TB include injection drug use; being a resident or employee in congregate settings such as prisons and jails, health care facilities, and homeless shelters; and, most notably, being a known contact of an active TB case. On average, 30% of household contacts to infectious TB cases have a positive tuberculin skin test (TST).

**RISK FACTORS FOR ACTIVE TB DISEASE:** Approximately 5% of infected persons develop active TB disease during the first year or two after infection. In another 2–5%, the disease will develop later in their lives. Certain medical conditions increase the risk that TB infection will progress to disease, the most important of which is HIV infection.

- Diabetes is an increasingly important risk factor for active TB. Diabetics have a 2-3 times higher risk of developing active TB if infected, compared to people without diabetes.

- Appendix 1. Tuberculosis Risk Factors, lists conditions associated with a higher risk of TB disease.
3. SCREENING

Screening for TB in correctional facilities involves ongoing surveillance for active TB disease, as well as detection of LTBI. Early detection and isolation of inmates with suspected pulmonary TB disease is critical to preventing widespread TB transmission. Identification of LTBI provides an opportunity for providing treatment to prevent future development of TB disease.

INTAKE TB SYMPTOM SCREENING

All inmates (including all holdover inmates) should be systematically screened for TB symptoms as part of intake screening. For non-English speaking inmates, it is critical that TB symptom screening questions be asked through an interpreter (either in-person or via language line).

<table>
<thead>
<tr>
<th>TB Questions</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BOP Electronic Medical Record (BEMR) Intake Health Screen</strong></td>
</tr>
<tr>
<td>• History of previous disease?</td>
</tr>
<tr>
<td>• Blood-tinged sputum?</td>
</tr>
<tr>
<td>• Night sweats?</td>
</tr>
<tr>
<td>• Weight loss?</td>
</tr>
<tr>
<td>• Fever?</td>
</tr>
<tr>
<td>• Cough?</td>
</tr>
</tbody>
</table>

CHEST RADIOGRAPH SCREENING

INTAKE CHEST X-RAYS (CXRs)

The following categories of inmates should have a CXR at intake:

• Inmates reporting TB symptoms (especially a cough for 2–3 weeks), regardless of TST results
• TST-positive inmates
• All HIV-infected inmates

Inmates with symptoms should have both a posterior-anterior (PA) and a lateral CXR. For asymptomatic inmates, a PA view is sufficient.

Some facilities that house inmates with a high incidence of TB may conduct routine CXR screening of all inmates entering the prison. Decisions about the use of routine CXR screening should be made in consultation with the Warden and the Regional and Central Office HSD staff.

CXRs DURING PREGNANCY:

• For pregnant women who are at higher risk for developing active TB disease, a CXR using lead shielding should be done immediately, even during the first trimester. Higher-risk scenarios include the following:
  ▶ Presenting with symptoms suggestive of TB disease
  ▶ HIV-positive (TST-positive or negative) and had close contact to a TB case
  ▶ TST-positive and a close contact to a smear-positive or cavitary case
• For lower risk TST-positive pregnant women, a CXR using lead shielding should be performed after the first trimester.

SCREENING FOR LATENT TB INFECTION

While persons with LTBI are usually asymptomatic and often unaware of past exposures to TB, they are at risk of developing infectious TB. Screening high-risk populations such as inmates and providing treatment for those with LTBI are important public health measures.

➤ Currently there are two types of methods approved by the U.S. Food and Drug Administration (FDA) for testing for LTBI—the tuberculin skin test (TST) and interferon-gamma release assays (IGRAs) blood tests. These methods, and their use in the BOP, are discussed in the next two sections.

TUBERCULIN SKIN TEST (TST)

The TST is an approved method for diagnosing *M. tuberculosis* infection in persons who do not have TB disease. Below is a discussion of indications, special considerations, administering and reading the TST, interpreting results, and two-step testing.

➤ Guidelines for tuberculin skin testing are summarized in Appendix 2.

🌟 TSTs have been demonstrated to be “false negative” in 25% of active TB cases.

🌟 A negative TST does not rule out the possibility of active TB.

INDICATIONS FOR TUBERCULIN SKIN TESTING

Inmates should be evaluated for TB infection with a TST, in accordance with BOP policy and the indications discussed below.

➤ See also the discussion of Special Considerations Regarding the TST below.

ACTIVE TB DISEASE IS CLINICALLY SUSPECTED: Tuberculin skin testing should be performed if active TB is clinically suspected and the inmate’s TST status is unknown.

INTAKE SCREENING:

A baseline TST will be obtained on all new intakes to the BOP, regardless of TST results from local jails or an inmate’s history of a prior positive TST, with the following exceptions:

➤ The inmate has documentation of a prior positive TST while incarcerated within BOP.

➤ The inmate has a history (either by self-report or clinically documented) of a severe reaction to a TST (e.g., a swollen, blistering, vesiculated reaction), which is considered a positive TST reaction.

➤ The inmate provides a credible history of treatment for LTBI (i.e., is able to describe the medication taken, and when, where, and how long it was taken).

➤ If an inmate is in holdover status with a short length of stay anticipated, and has documentation of a negative TST in the last year while incarcerated, then that TST is considered valid for screening purposes.

➤ It is critically important that holdover inmates receive a TB symptom screen at intake.
There is a unique reason not to repeat a TST (as approved by the Regional Medical Director) such as repeated admissions from local detention facilities over a short period.

**FOR FOREIGN-BORN INMATES:** Consider performing two-step tuberculin skin testing for foreign-born inmates who have not been tested in the previous 12 months. A self-report of being tested within the last year is a sufficient reason not to perform a two-step test.

► See *Booster Phenomenon and Two-Step Testing* at the end of the section on TSTs.

**ANNUAL SCREENING:** Tuberculin skin testing should be performed annually unless there is documentation of a prior positive TST or history of active TB disease.

**TB CONTACT INVESTIGATION:** Tuberculin skin testing should be done for contacts of an inmate determined to have active TB.

► See *Medical Evaluation of Contacts* under Section 7, Contact Investigations.

### SPECIAL CONSIDERATIONS REGARDING THE TST

**PREGNANCY:** Pregnancy is not a contraindication to tuberculin skin testing.

**BACILLUS CALMETTE-GUERIN (BCG) VACCINATION:** BCG vaccination is not a contraindication to tuberculin testing. TST reactivity resulting from BCG vaccination does not correlate with protection against TB. Since there is no reliable method for distinguishing tuberculin reactions caused by BCG from those caused by infection with *M. tuberculosis*, persons with a history of BCG vaccination whose TST is positive should be considered infected with *M. tuberculosis*.

### ADMINISTERING AND READING TSTs

**TST TRAINING:** TSTs should only be performed by health care workers who have had formal skills training in administering, reading, and interpreting the test. If the TST is placed or read incorrectly, the results may be inaccurate. The BOP has developed a TST training program including on-line training and skills assessment. See Sallyport/Health Services Division/Infectious Diseases / A-Z Topics.

**PRODUCT HANDLING:**

► Only BOP Formulary tuberculin solution should be used.
► Skin tests should be administered as soon as possible after the tuberculin syringe has been filled. Tuberculin should not be drawn up in advance of testing. The reason for this is that tuberculin adsorbs to the plastic of the syringe; if syringes are drawn up in advance the amount of tuberculin administered may be reduced by adsorption.
► The tuberculin test solution should be refrigerated (not frozen) and stored in the dark as much as possible (exposure to strong light should be avoided).

**ADMINISTRATION OF THE TST:**

► The TST should be administered by the Mantoux method, which consists of intradermal injection of 0.1 ml of PPD tuberculin containing 5 tuberculin units (TU) into the volar or dorsal surface of the forearm, using a disposable tuberculin syringe. The left forearm is the preferred site for testing. A skin area away from superficial veins and free of lesions should be selected.
► A 5 mm tense white wheal should appear at the injection site. If this does not appear, replace the test at least 2 inches away from the initial injection site.
► Gloves are optional for administering TSTs and can be used on a case-by-case basis.
► Wash hands before and after placing and reading a TST. Alcohol-based hand sanitizer can be used.

**READING THE TST:**
► The TST should be read by a trained health care worker 48–72 hours after injection.
  • A positive reaction can be measured up to one week after testing and is considered valid; however, readings after 72 hours tend to underestimate the true size of induration.
  • A negative reaction read after 72 hours is invalid, and the test should be repeated.
► The test is “read” by measuring in millimeters (mm) the largest diameter of the indurated area (palpable swelling) on the forearm. The diameter of the induration should be measured transversely to the long axis of the forearm.
► Erythema (redness) without induration is not significant.
► The TST results should always be documented in millimeters, not as positive or negative. If there is no reaction (or just erythema), record “0 mm.”

**INTERPRETING SKIN TEST REACTIONS**

**TST CUT-POINTS:**
Two cut-points for defining a positive TST are indicated in correctional facilities, based on risk factors for TB infection and TB disease in infected inmates (5 mm for inmates with specific risk factors and 10 mm for all others).
► See “TST Cut-Points” in Appendix 2, Tuberculin Skin Testing Guidelines.

**TST REACTORS VS. CONVERTORS:**
► A **TST reactor** is anyone who has a positive TST. A **TST convertor** is a TST reactor whose TST has increased 10 mm or more in a two-year period.
► This distinction is important because TST convertors have a higher risk of developing TB disease in the two years following infection and are considered high priority for LTBI treatment.

**BOOSTER PHENOMENON AND TWO-STEP TESTING**
Certain individuals infected with *M. tuberculosis* will have a negative TST when tested many years after their initial infection. This skin test, however, may stimulate or “boost” the immune system’s ability to react to tuberculin and cause a positive reaction to subsequent tests. This booster phenomenon can be induced more than a year after an initial test. Two-step testing is a technique used to help distinguish between “boosted” reactions and reactions due to new infections.
Consider two-step testing for newly sentenced inmates in the following categories who are at high risk for boosting (if they have not received a TST in the last year and if repeated annual testing is anticipated):

- Foreign-born inmates
- Inmates with a history of BCG vaccination
- Other inmates as medically indicated with suspected previous exposures to *M. tuberculosis*

### Two-step Tuberculin Skin Testing Procedure

- Place a TST.
- If the initial TST reaction is negative, a second test is placed 1–3 weeks later.
  - If the second test is *negative*, the person is considered uninfected. (Any subsequent positive test would be considered new infection)
  - If the second test is *positive*, the person is a TST reactor (but not a TST convertor) and managed accordingly. (See *Interpreting Skin Test Reactions*.)

➤ Note: If the inmate received a TST in the last year this is considered equivalent to a two-step test and a second "step" test is not needed.

### Interferon-Gamma Release Assays (IGRAs)

Interferon-gamma release assays are whole-blood tests that can aid in diagnosing *M. tuberculosis* infection. Two IGRAs have been approved by the FDA and are commercially available:

- **QuantiFERON®-TB Gold In-Tube Test (QFT-GIT)**
- **T-SPOT®.TB test (T-Spot)**

IGRAs measure a person’s immune reactivity to *M. tuberculosis*. White blood cells from most persons that have been infected with *M. tuberculosis* will release interferon-gamma (IFN-g) when mixed with antigens (substances that can produce an immune response) derived from *M. tuberculosis*. To conduct the tests, fresh blood samples are mixed with antigens and controls.

★ *Similar to the TST, IGRAs test for TB infection. They are NOT tests for active TB disease.*

★ *In 10–25% of active TB cases, IGRAs have been demonstrated to be “false negative.” A negative IGRA does not rule out the possibility of active TB.*
THE USE OF IGRAs IN THE BOP

The use of IGRAs for screening purposes is being evaluated for future use in the BOP.

- Currently, IGRAs shall not be used for routine screening inmates for LTBI.
- The use of IGRAs may be considered in the diagnostic work-up of inmates with suspected active tuberculosis, particularly when the TST result is negative. They also may be considered for use in inmates with questionable TST results with prior approval of the Regional Medical Director.
- Some inmates may enter BOP with documentation of prior IGRA results. These results (positive or negative) should be considered as evidence of the presence or absence of LTBI.
- Record of a prior positive IGRA test should be considered as evidence of LTBI, i.e., equivalent to a positive TST. There is generally no reason to perform a TST to confirm it.

ADVANTAGES OF IGRAs OVER THE TST

- Only a single patient visit is required to conduct the test.
- Results can be available within 24 hours.
- IGRAs do not “boost” the response measured by subsequent tests.
  - See discussion of booster phenomenon with TSTs.
- Prior BCG vaccination does not cause a false-positive IGRA result.

DISADVANTAGES OF IGRAs COMPARED TO THE TST

- Blood samples must be processed within 8–16 hours after collection, while white blood cells are still viable.
- Errors in collecting or transporting blood specimens, or in running and interpreting the assay, can decrease the accuracy of IGRAs. It is critically important to carefully follow all procedures for handling specimens and timing of shipments.
- There is limited data on the use of IGRAs to predict who will progress to TB disease in the future.
- Tests may be expensive.

OTHER CONSIDERATIONS REGARDING IGRAs

- IGRA interpretations are based on the amount of IFN-g that is released or on the number of cells that release IFN-g.
- IGRAS, as with TSTs, should be used as an aid in diagnosing infection with \textit{M. tuberculosis}.
  - \textbf{POSITIVE} test result – suggests that \textit{M. tuberculosis} infection is likely.
  - \textbf{NEGATIVE} result – suggests that infection is unlikely.
  - \textbf{INDETERMINATE} result – indicates an uncertain likelihood of \textit{M. tuberculosis} infection.
  - \textbf{BORDERLINE} test result (T-Spot only) – also indicates an uncertain likelihood of \textit{M. tuberculosis} infection.
**4. LATENT TUBERCULOSIS INFECTION (LTBI)**

All inmates with a positive TST or IGRA should be clinically evaluated, have a CXR to rule out active TB, and be considered for treatment of LTBI. Treatment substantially reduces the likelihood that a person with LTBI will develop active TB in the future.

Currently there are several options for treatment of LTBI. The BOP has adopted the 12-week, 12-dose regimen of isoniazid (INH) and rifapentine (RPT) as the standard BOP treatment for LTBI, to be utilized unless there are contraindications for its use.

See Appendix 3a, Standard Treatment for Latent TB Infection.

**BASELINE EVALUATION FOR LTBI**

★ The treatment of LTBI should NEVER be initiated until active TB disease has been eliminated as a potential diagnosis.

A diagnosis of LTBI (positive TST or IGRA) requires that active TB disease be excluded by medical evaluation that includes assessment of the following:

- **TB SIGNS AND SYMPTOMS:** Cough, fever, night sweats, weight loss, hemoptysis.

- **CXR:**
  - A posterior-anterior (PA) view is sufficient in asymptomatic inmates; a lateral should also be performed if there is any suspicion for active TB.
  - In the asymptomatic inmate, a CXR must be performed within 14 days of identifying the positive TST or IGRA.
  - For the purpose of ruling out TB in asymptomatic persons prior to starting treatment for LTBI, a CXR is “good” for six months in HIV-seronegative inmates and for one month in HIV-positive inmates.
  - CXRs, other than baseline, are not indicated during treatment of LTBI unless symptoms of TB disease develop during treatment.

See discussion of CXRs during pregnancy under “Chest Radiograph Screening” in Section 3.

- **MEDICAL HISTORY** should include review of the following:
  - Risk factors for TB (see Appendix 1, Tuberculosis Risk Factors).
  - Prior treatment for TB or LTBI.
  - Preexisting medical conditions that may complicate treatment.
  - Symptoms of active TB disease, hepatitis, liver disease, and pregnancy.
  - Current medications, with attention to potential drug interactions. There are significant drug interactions with RPT, including some drugs for which RPT is contraindicated.

See Appendix 3a for a list of these drugs.
• **TARGETED EXAMINATION** should be performed by a clinician for systemic signs of active TB disease, as well as signs of hepatitis.

• **HIV TESTING** shall be performed on an opt-out basis for all inmates with a positive TST or IGRA (unless previously tested for HIV), since HIV co-infection significantly increases the risk of developing active TB.

• **DETERMINE PROJECTED RELEASE DATE TO ASSESS ELIGIBILITY FOR TREATMENT.**
  
  ➤ **IN GENERAL,** LTBI treatment is not prescribed for inmates whose projected release date is sooner than the anticipated completion of the 12-week INH-RPT treatment regimen, or whose projected release date is unknown. Pretrial inmates and inmates in holdover status should ordinarily not be prescribed LTBI treatment.

  ➤ **EXCEPTION:** Inmates with the following risk factors should be started on LTBI treatment regardless of their expected duration of incarceration:
    - HIV co-infection or other immunocompromised condition
    - Close contact with an active TB case
    - Recent TST convertor (10 mm or more increase in reaction size within two years)

  ➤ These high-risk inmates with a projected release date of less than 12 weeks hence should be started on 9-month INH, not 12-week INH-RPT, because often 12-week INH-RPT is not available in the community. (See Appendix 3b for details on the 9-month INH regimen.)

  ➤ See also **Section 9, Discharge Planning** for inmates who will require continuation of treatment after release.

• **BASELINE LABORATORY TESTS** prior to initiating LTBI treatment:
  
  ➤ **HEPATITIS B SURFACE ANTIGEN (HBsAg) AND ANTI-HCV** tests should be performed if the inmate has risk factors for viral hepatitis.

  ➤ **ALT AND AST:** Obtain for all inmates being considered for LTBI treatment. If liver transaminases are elevated, liver function tests (e.g., bilirubin) should also be assessed.

  ➤ **COMPLETE BLOOD COUNT** with platelets should be obtained if a 12-week INH-RPT is being considered.

  ➤ **SPUTUM EVALUATION** is not routinely indicated for persons being considered for LTBI treatment. However, for inmates with CXRs suggestive of old healed TB, sputum (if producible) should be obtained to screen for active TB disease: AFB smear, nucleic acid amplification test (NAAT), and culture.

  ➤ See **Old Healed TB vs. Active TB** in Section 5 for guidance on evaluating and treating inmates with evidence of old healed TB.
INDICATIONS FOR TREATMENT OF LTBI

Clinical indications for the treatment of LTBI are based on the inmate’s TST reaction in millimeters or a positive IGRA, the relative risk of developing TB disease, and risk factors for drug side effects. Treatment of LTBI should be considered for all TST-positive or IGRA-positive inmates, regardless of age—when no medical contraindications to treatment exist, and previous adequate treatment has not been provided. BCG vaccination history should be ignored.

*Give highest priority for LTBI treatment to inmates who have an increased risk of developing active TB disease:*

- **HIV CO-INFECTION** is the most significant risk factor for the development of active TB; therefore, co-infected TST reactors are a very high priority for LTBI treatment.
- **DIABETES MELLITUS** which increases risk of TB disease by 2-3 fold.
- **OTHER IMMUNOSUPPRESSIVE CONDITIONS OR THERAPY:** Inmates on immunosuppressive therapy (including a history of organ transplantation with immunosuppression, on chronic steroid therapy, or those on anti-TNF alpha therapy) should also receive priority treatment for LTBI.
- **RECENT CONVERTORS:** Inmates whose TST has increased 10 millimeters or more within the past 24 months are at relatively high risk for developing TB, and are therefore high-priority candidates for LTBI treatment.
- **ABNORMAL CXR (OLD HEALED TB):** See *Old Healed TB vs. Active TB* in Section 5.
- **OTHER HIGH RISK MEDICAL CONDITIONS:** See Appendix 1, which lists conditions associated with a higher risk of TB disease.

TREATMENT REGIMENS FOR LTBI

MEDICATION LOOK-ALIKE /SOUND-ALIKE ALERT

Do not confuse Rifapentine (RPT), which is used for treatment of latent TB infection with Rifampin (RIF) or Rifabutin (RBU/RBT), which are used for treatment of active TB disease.

CDC RECOMMENDATIONS: In 2011, the Centers for Disease Control and Prevention (CDC) recommended the use of a 12-week isoniazid-rifapentine (INH-RPT) regimen as an equal alternative to the 9-month INH regimen for treatment of LTBI in individuals who are at high risk for developing active TB. The CDC also recommended that the 12-week INH-RPT regimen be considered in situations such as correctional settings where it offers significant practical advantages, i.e., 12 once-weekly doses INH-RPT vs. 76 twice-weekly doses INH.

* The 2011 CDC article is listed under DIAGNOSIS AND TREATMENT in the References section and is available at: [http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6048a3.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6048a3.htm)

12-WEEK INH-RPT ADOPTED AS STANDARD BOP REGIMEN: In 2014, the BOP completed a pilot evaluation of the 12-week INH-RPT regimen in seven BOP facilities. Of 463 inmates starting 12-week INH-RPT, 424 (92%) completed it, significantly higher than published completion rates for INH. Treatment was discontinued in 4% of the inmates due to adverse effects. Abdominal
pain, appetite loss, fever/chills, nausea, rash/hives, and sore muscles were associated with treatment discontinuation. Based on the results of the pilot evaluation, the BOP adopted the 12-week INH-RPT as the standard regimen for treatment of LTBI unless it is contraindicated.

• **DRUG INTERACTIONS:** Like all rifamycins, RPT induces activity of the cytochrome P-450 system, resulting in drug interactions with substrates of this enzyme system—warfarin, hormonal contraceptives, antiretroviral agents, anti-HCV agents, methadone, sulfonylureas (oral hypoglycemic), and anti-epileptic drugs.

> There are numerous contraindications to Rifapentine. See list **Appendix 3a**.

• **ALTERNATIVE REGIMENS:** If 12-week INH-RPT is contraindicated or adverse effects occur on the regimen, consideration can be given to utilizing alternative regimens for LTBI treatment, including 9-month INH (administered twice weekly) and 4-month rifampin (administered daily).

• **FOR ALL LTBI REGIMENS:**
  - All doses of medication must be directly observed by a health care provider.
  - Determination of treatment completion is based on counted doses administered, NOT time elapsed.

> See **Appendix 3a**, Standard Treatment for LTBI, and **Appendix 3b**, Alternative Regimens for Treatment of LTBI, for specific recommendations regarding contraindications, medication dosing, drug interactions, summary of side effects, etc.

**SPECIAL CONSIDERATIONS IN TREATING LTBI**

**TREATMENT REFUSALS**

Inmates who refuse treatment for LTBI should sign a refusal form to be kept in their medical record, documenting their declination of treatment; the LTBI “Prophy” Problem Code should be revised. Group counseling or other structured educational efforts should be considered for inmates who refuse treatment for LTBI when treatment is clearly indicated.

**MONITORING INMATES WHO REFUSE TREATMENT:**

Two categories of inmates who refuse treatment for LTBI—or have treatment discontinued because of drug side effects, nonadherence, or other reasons—should be monitored in accordance with the following:

• **Inmates with HIV infection (or unknown HIV status) or other immunosuppressive conditions and TST > 5mm:** Semi-annual CXRs and clinician evaluations for symptoms and signs of pulmonary TB performed indefinitely for HIV-infected inmates with a CD4+ T cell count < 200 cells/mm$^3$.

• **HIV-seronegative inmates who are recent convertors or close contacts of active TB cases:** Semi-annual CXRs and clinician evaluations for symptoms and signs of pulmonary TB; for a 2-year period. (See **Interpreting Skin Test Reactions** for description of recent convertor.)
Both of these groups should be educated at the time of their symptom assessment about the importance of promptly reporting to health services if they develop TB symptoms, especially a persistent cough.

**CONTRAINDICATIONS TO LTBI TREATMENT**

Treatment of LTBI should not be initiated if contraindications to treatment exist. Contraindications to LTBI treatment include, but are not necessarily limited to, the following:

- Radiologic or clinical evidence of active TB disease.
- Symptoms or signs of active hepatitis or other medical conditions that would complicate treatment.
  - Inmates with significant elevations in liver transaminases should be considered for LTBI treatment only if they are at high risk of developing active TB disease. Consultation with a physician with expertise in treating LTBI is recommended.
- History of adverse reactions to medications prescribed for LTBI.

**HIV Co-Infection**

- **12-week INH-RPT is contraindicated for HIV-infected inmates on antiretroviral therapy. 9-month INH treatment is recommended instead.**
- Persons with HIV infection and LTBI are at significant risk of developing active TB disease and are therefore considered priority candidates for treatment.
- Inmates with HIV infection who are close contacts of a person with infectious TB disease should be considered for treatment, regardless of TST results.
- Inmates with HIV infection who have respiratory symptoms, unexplained fever, or weight loss, should also have sputum submitted for bacteriologic cultures, since active TB disease in immunocompromised hosts is often difficult to diagnose.

**Pregnancy**

- **RPT is contraindicated in pregnancy.**
- Pregnancy itself does not significantly influence the pathogenesis of TB or the risk of LTBI progressing to active TB disease; therefore, treatment of LTBI is not routinely recommended during pregnancy.
- In most cases, LTBI treatment should be prescribed 1–2 months following delivery.
- Pregnant women at high risk of developing TB disease (e.g., positive TST and history of close contact to an active TB case; recent converters; or concurrent HIV infection or other immunosuppressive conditions) should be considered for INH treatment of LTBI during pregnancy, with close monitoring for hepatitis. No harmful effects on the fetus have been observed with INH therapy.
OLD HEALED TB

- See Section 5, Diagnosis of Active TB Disease, for discussion of the diagnostic work-up of inmates with radiographic presentations that may represent old healed TB.

BCG VACCINATION

A history of BCG vaccination, with or without a BCG scar, should be ignored as a factor in deciding whether to offer treatment for LTBI.

CONTACTS TO MULTIPLE DRUG RESISTANT TB (MDR-TB)

Consultation with the Central Office Infection Prevention and Control Program is required when treating contacts of persons with MDR-TB.

ANTI-TNF ALPHA DRUGS (TUMOR NECROSING FACTOR ALPHA ANTAGONISTS)

Anti-TNF alpha drugs, a class of immunosuppressive drugs used for treatment of inflammatory conditions, such as psoriasis and rheumatoid arthritis, are associated with increased risk of TB disease. Inmates with a history of a positive TST (cut-point of > 5mm) should start treatment for LTBI before commencing TNF-α blocking agents. Consider postponing TNF-α antagonist therapy until the conclusion of treatment for LTBI or TB disease.

- See the list of anti-TNF alpha drugs in Appendix 1.

MONITORING LTBI TREATMENT

- Guidelines for monitoring LTBI treatment are summarized in Appendix 3c, Treatment for LTBI: Baseline and Ongoing Monitoring.

CLINICIAN EVALUATIONS

- At a minimum, patients on treatment for LTBI should be evaluated by a physician or qualified mid-level provider at the initiation of treatment, when signs and symptoms of adverse reactions occur, and whenever treatment is interrupted.
- Inmates with baseline elevations of liver transaminases or other complicating medical conditions should be followed closely.

INMATE COUNSELING

Inmates should be counseled by health care staff about the importance of adherence to every dose of treatment for LTBI, potential drug side effects, signs and symptoms of hepatitis and the reason for pyridoxine (vitamin B6) co-administration.

BASELINE/ONGOING LABORATORY TESTS

All inmates on LTBI treatment should have baseline liver transaminases measured. Those treated with 12-week INH-RPT or 4-month RIF also require a baseline complete blood count.
with platelets. ALT and AST should be monitored periodically for inmates with risk factors for hepatotoxicity

**Treatment for LTBI should ordinarily be discontinued under the following circumstances:**

- Liver transaminases exceeding three times the upper limit of normal, if the inmate has symptoms of hepatitis.
- Liver transaminases exceeding five times the upper limit of normal, if the inmate is asymptomatic.

**MONITORING DRUG SIDE EFFECTS**

- All inmates on LTBI treatment require regular monitoring:
  - Inmates on 12-week INH-RPT shall be monitored for adverse effects weekly.
  - Inmates treated with 9-month INH or 4-month RIF shall be monitored monthly.
- Monitoring shall be recorded in the BEMR Latent TB flow sheet. For inmates on INH-RPT, additional questions should be asked during the weekly visits with the responses recorded in the Comments section of the BEMR flowsheet.
  
  ➤ See adverse reactions Appendix 3c.

- **At each encounter, patients should be instructed in their preferred language to seek medical attention immediately** if they have fever, yellow eyes, dizziness, rash, or aches—or greater than one day of nausea, vomiting, weakness, abdominal pain, or loss of appetite. LTBI treatment (regardless of regimen) shall be withheld while the cause of symptoms is being determined and the inmate is referred to a clinician for further evaluation.

**INTERRUPTION OR DISCONTINUATION OF TREATMENT**

Inmates failing to complete a treatment regimen for LTBI on two or more occasions should be evaluated to determine if additional retreatment efforts are clinically prudent—based on the inmate’s risk factors for TB disease, previous cumulative doses of administered treatment, and anticipated adherence to therapy.

The following practical decision rule should be applied when reinstituting therapy for inmates who have stopped taking their medications for LTBI or who have had therapy interrupted for medical reasons:

- If 50% or fewer of the doses have been missed within the intended treatment period, then add doses onto the end of treatment.
- If greater than 50% of the doses have been missed within the intended treatment period, then restart therapy.

➤ *In either situation, when therapy is reinstituted after an interruption of more than two months, a medical examination to rule out active TB is indicated.*
**DOCUMENTATION OF TREATMENT REGIMEN**

Treatment of LTBI should be documented utilizing the appropriate problem code in the electronic medical record.

- Drug treatment completion is measured in terms of total number of doses ingested, NOT the amount of time elapsed.

**STRATEGIES FOR A SUCCESSFUL LTBI TREATMENT PROGRAM**

Clinicians involved in the BOP 12-week INH-RPT pilot evaluation reported that the high rate of completion may have been achieved for more reasons than the simple fact that the regimen was simpler and shorter. The following strategies that were employed during the pilot evaluation should be considered when utilizing this regimen:

- **One health care professional was dedicated to oversee the program** and conduct the weekly symptom reviews and administered medication. This health care worker was selected on the basis of available staff resources at the institution (e.g., nurse, infection control staff, pharmacist, mid-level provider). Thus, inmates received ongoing individual support from one health professional for promoting compliance and completing the regimen.

- **Weekly call-outs were used to structure the INH-RPT clinics** rather than via pill-line. The weekly call-out system resulted in groups of inmates waiting together to be seen, resulting in the formation of informal support groups for completing the regimen.

- **Pilot sites frequently started the inmates on INH-RPT in cohorts** to facilitate efficient tracking of the baseline evaluations and lab monitoring. This approach also allows for educational efforts to be provided to groups of inmates who are all starting the regimen at the same time.
5. Diagnosis of Active Tuberculosis Disease

The expedient diagnosis of contagious TB is critical for providing effective treatment and for preventing TB transmission in the correctional setting. The diagnosis of TB disease frequently requires expert medical consultation, which can be accessed through the Central Office Infection Prevention and Control Program.

Guidelines for the diagnostic work-up of patients with suspected TB are summarized in step 1 of Appendix 4, TB Case Management Checklist.

Diagnostic Issues

Although many inmates with active TB disease are symptomatic and have a positive TST and a characteristically abnormal CXR (upper lobe/cavitary lesions), many other cases of active TB may not be so obvious. Correctional health care providers should maintain a high index of diagnostic suspicion for TB and be alert to the following:

- **Inmates with active TB disease may appear healthy and deny symptoms.**
- **Important risk factors for TB** are foreign birth, HIV infection, alcoholism, chronic renal failure, diabetes mellitus, neoplastic diseases, anti-TNF alpha drugs, and drug abuse.
- **A negative TST or IGRA does not rule out active TB.**
- **Negative AFB smears from sputum or bronchoscopy specimens do not rule out active TB.**
- **Negative AFB cultures in persons with abnormal CXRs consistent with TB do not rule out TB.**
  
  See **Culture-Negative Pulmonary TB** in Section 6. See also Appendix 6c, Tuberculosis Treatment Regimens in Special Situations.

- **Fluoroquinolones (e.g., ciprofloxacin, levofloxacin, moxifloxacin) are highly effective drugs for treating active TB.** In general, fluoroquinolones should be avoided when active TB is in the differential diagnosis because it can confuse the diagnostic work-up. For example, it is impossible to determine if clinical improvement on the fluoroquinolone is related to improvement of symptoms caused by TB or caused by another problem, i.e., community-acquired pneumonia.

- **Extrapulmonary TB can occur in nearly any organ of the body** and should always be considered when an inmate presents with a fever or infection of unknown etiology that does not respond to routine antibiotic therapy.

- **Evidence of necrotizing or caseating granuloma on pathology report is presumed to be indicative of TB unless proven otherwise.**

Medical History and Physical Exam

Inmates who present with signs and symptoms of TB or an abnormal CXR consistent with TB should be evaluated by a physician or mid-level provider. The physical examination is not useful for confirming or ruling out a TB diagnosis, but can provide valuable information on the extent of TB disease, signs of extrapulmonary TB, and the presence of relevant co-morbid conditions.

Components of the medical history are summarized in Step 1 of Appendix 4, TB Case Management Checklist.
CHEST RADIOGRAPH MANIFESTATIONS OF TB

Below are listed typical radiographic features of pulmonary TB:

- **LOCATION:** Apical and/or posterior segment of right upper lobe, apico-posterior segment of left upper lobe, or superior segment of either lobe. (Reactivation pulmonary TB commonly presents with cavitory upper lobe disease.)

- **INFILTRATE:** Fibronodular, coalescence or consolidation, pneumonia.

- **CAVITIES:** Thick, moderately irregular walls; air-fluid levels are uncommon.

- **VOLUME:** Progressive, often rapid loss of volume with the involved segment(s) or lobe(s).

- **ADENOPATHY:** Hilar adenopathy (common in HIV-infected persons and in young children).

  → Pulmonary TB, however, may exist even when the CXR is completely normal or mildly abnormal, particularly with HIV co-infection. With advanced HIV infection, other atypical presentations of active TB disease are common, including lower lung zone infiltrates without cavities, and intrathoracic lymphadenopathy without pulmonary infiltrates.

DIAGNOSTIC MICROBIOLOGY

*It is recommended that, if possible, sputum specimens for AFB be sent to a public health laboratory in the state where the facility is located.* Each institution should contact the public health laboratory in their state and determine whether this is feasible. The institution should a priori acquire appropriate specimen containers and lab slips, and determine procedures for specimen submission.

→ **Detailed recommendations on sputum collection, sputum induction, and associated infection control measures are provided in Appendix 5, Sputum Collection/Induction Procedures.**

AFB SMEEARS

- AFB smears can be processed and reported within hours of receiving a sputum specimen and thus provide a rapid diagnostic tool for detecting *M. tuberculosis*.

- AFB smears are not specific for *M. tuberculosis*, since the presence of other nontuberculous mycobacteria can also result in positive AFB smears.

  → **Negative AFB smears from sputum or bronchoscopy DO NOT rule out active TB disease.**

NUCLEIC ACID AMPLIFICATION TESTS (NAATS)

- Sometimes referred to as “rapid tests” or “PCR tests,” NAATs can detect *M. tuberculosis* within hours and are useful for the rapid diagnosis of TB disease in certain clinical situations.

- Two licensed tests are available: MTD® and Amplicor®.

- A NAAT should be performed on at least one respiratory specimen from each patient who has signs and symptoms of pulmonary TB and for whom a diagnosis of TB is being considered, but has not yet been established.

- It may be necessary to specifically request that this test be performed.
• Confirmatory bacterial cultures and sensitivities should also be obtained, regardless of the results of the NAAT.

**TABLE 1. INTERPRETATION OF NUCLEIC ACID AMPLIFICATION TEST RESULTS**

<table>
<thead>
<tr>
<th>AFB Smear</th>
<th>NAAT</th>
<th>Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Positive</td>
<td>Positive</td>
<td>Presume the patient has TB and begin anti-TB treatment while awaiting culture results.</td>
</tr>
<tr>
<td>Negative</td>
<td>Positive</td>
<td>Use clinical judgment whether to begin anti-TB treatment while awaiting culture results and determine if additional diagnostic testing is needed. Consider testing an additional specimen using NAA to confirm the NAA result. A patient can be presumed to have TB, pending culture results, if two or more specimens are NAAT positive.</td>
</tr>
</tbody>
</table>
| Positive  | Negative| A test for inhibitors should be requested from the lab and an additional specimen should be tested with NAA. Sputum specimens might contain inhibitors that prevent or reduce amplification and cause false-negative NAA results.  
- If inhibitors are detected, the NAAT is of no diagnostic help for this specimen. Use clinical judgment to determine whether to begin anti-TB treatment while awaiting results of culture and additional diagnostic testing.  
- If inhibitors are not detected, use clinical judgment to determine whether to begin anti-TB treatment while awaiting culture results and determine if additional diagnostic testing is needed. A patient can be presumed to have an infection with nontuberculous mycobacteria if a second specimen is smear positive, and NAAT is negative and has no inhibitors detected. |
| Negative  | Negative| Use clinical judgment to determine whether to begin anti-TB treatment while awaiting results of culture and additional diagnostic tests. Currently available NAATs are not sufficiently sensitive (detecting 50–80% of AFB smear-negative, culture-positive pulmonary TB cases) to exclude the diagnosis of TB in AFB smear-negative patients suspected to have TB. |

Reference: CDC. Updated guidelines for the use of nucleic acid amplification tests in the diagnosis of tuberculosis. MMWR. 2009;58(01):7–10. Available at: [http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5801a3.htm?s_cid=mm5801a3_e](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5801a3.htm?s_cid=mm5801a3_e)

**AFB CULTURES**

• All clinical specimens suspected of containing *M. tuberculosis* should be inoculated onto culture media. Culturing is more sensitive than microscopy (AFB smear positivity), allows for the precise identification of the mycobacterial species, and permits drug susceptibility testing and genotyping. Once a positive AFB culture is obtained, it requires identification to determine if it is *M. tuberculosis* or another type of acid-fast bacteria.

• Laboratory contamination (resulting in false positive *M. tuberculosis* cultures) should be suspected when the specimen is AFB smear-negative, has a single positive culture, a low colony count (on conventional media), and a clinical presentation uncharacteristic of TB.

• If a private lab is used, it may be necessary to specifically request “AFB culture,” in addition to an “AFB smear.”
Negative cultures do not rule out active TB in a person whose CXR is consistent with active TB (with or without TB symptoms) and for whom there is no alternative diagnosis. See Culture-Negative Pulmonary TB in Section 6.

**DRUG SUSCEPTIBILITY TESTING**

- Drug susceptibility testing should be performed on all cultures positive for *M. tuberculosis*.
- For culture-positive patients, DO NOT switch from the initial 4-drug phase of treatment to two drugs until after receipt of drug susceptibilities indicating drug sensitivity. Seek consultation from Regional/Central office staff if drug resistance is identified.

**RAPID TESTS FOR DRUG RESISTANCE**

- Rapid tests for drug resistance are available and should be requested from local or state health departments for inmates with suspected tuberculosis who are AFB smear-positive and who have risk factors for drug resistance—such as history of previous treatment for active tuberculosis or born in parts of the world with high rates of multiple drug-resistant TB (especially Eastern Europe, Asia, and Africa).
- These tests also should be requested in the context of large contact investigations where there is evidence of significant TB transmission.

**DNA FINGERPRINTING**

DNA fingerprinting (genotyping) of the organism is indicated for investigating possible TB outbreaks or laboratory contamination, in consultation with state health departments and the Central Office HSD.

**OLD HEALED TB VS. ACTIVE TB: A DIAGNOSTIC CHALLENGE**

The evaluation of inmates with abnormal CXRs suggestive of prior TB disease is complex and often requires expert consultation. Given the high-risk congregate settings in our prisons, inmates with radiographic findings suggestive of TB require a more aggressive work-up than might be indicated in the community.

**DIAGNOSIS**

Old healed TB presents a different radiologic appearance from active TB. In the BOP, this presentation is most often encountered in foreign born inmates. Dense pulmonary nodules, with or without visible calcification, may be seen in the hilar area or upper lobes. Smaller nodules, with or without fibrotic scars, are often seen in the upper lobes, and upper-lobe volume loss often accompanies these scars.

Asymptomatic inmates with abnormal CXRs suggestive of previous infection with no history of treatment are at increased risk for active TB and should be further evaluated. Obtain a TST if no result is available. Sputum examination obtained in an AIIR is usually warranted to rule out active TB disease. Obtain three consecutive sputum samples, at least eight hours apart, including one early morning specimen. One of those tests should be a NAAT, if available.

> The criteria for discontinuation of isolation are outlined in Appendix 7.
If sputum smears and NAAT are negative, and the inmate’s symptoms or radiographic findings cannot otherwise be clinically explained, further diagnostic evaluations (e.g., bronchoscopy) for active TB disease should be considered. TB expert consultation, including review of chest radiographs by TB experts, can be accessed through the Regional/Central Office Infection Prevention and Control Program.

**TREATMENT OPTIONS**

There are two treatment options for the asymptomatic inmate with an abnormal CXR suggestive of prior disease, whose sputum smears and NAAT are negative, and for whom there is no alternative diagnosis to explain the pulmonary abnormality.

1. **Start presumptive treatment for active TB with daily 4-drug RIPE treatment** (rifampin, isoniazid, pyrazinamide, and ethambutol).
   - If cultures all come back negative, then a CXR is repeated in 8 weeks. If the CXR is improved, then this is considered culture-negative TB, and treatment is continued for an additional 8–16 weeks.
   - See Culture Negative Pulmonary TB in Section 6.
   - If the CXR is unchanged, then 8 weeks of RIPE is considered equivalent to 9 months of INH, and should be coded as “complete LTBI treatment.”

2. **For TST-positive inmates, standard treatment for LTBI can be initiated**—but ONLY AFTER receipt of negative cultures results (usually in 6 weeks).

**EXTRAPULMONARY TB**

Extrapulmonary TB is usually more difficult to diagnose than pulmonary TB. Presentations may include fever, lymphadenitis (painless swelling of one or more lymph nodes), pleuritis, pericarditis, renal disease (mild dysuria/hematuria/flank pain/sterile pyuria), skeletal disease (arthritis/bone pain/bone deformities), meningitis, peritonitis, and epididymitis.

- Patients suspected of having extrapulmonary TB should also undergo a CXR to rule out pulmonary TB.
- Sputum for AFB should routinely be collected for persons with suspected extrapulmonary TB.
- Evidence of necrotizing or caseating granuloma on pathology reports from any site is presumed to be indicative of TB, unless proven otherwise. It is generally treated with a standard 6-month TB treatment regimen.

**REPORTING SUSPECTED/CONFIRMED TUBERCULOSIS CASES**

Any inmate diagnosed with suspected or confirmed TB should be promptly reported to the Regional and Central Office HSD—and to the local health department in the jurisdiction where the facility is located—utilizing the BP-A0665 Tuberculosis Case/Suspect and Referral Form.

- Inmates with suspected TB should be reported, even if there is no bacteriologic confirmation of the case.
• The BP-A0665 form shall be filed as a flow sheet in the electronic medical record. This form is designed to be updated as additional information becomes available, with the updates posted in BEMR.

• At the completion of treatment the form should be completed summarizing the outcome, i.e., treatment completed, released, TB ruled-out, and again filed in BEMR. This final update of the form provides a concise summary of the TB diagnosis and treatment for future reference.

• If a Witness Security (WITSEC) case is diagnosed with active TB, this should be reported first to the Inmate Monitoring Section of the Correctional Programs Branch—prior to reporting the case to local health authorities.

6. TREATMENT OF TUBERCULOSIS DISEASE

★ The goals of TB treatment are to interrupt TB transmission, prevent acquisition of drug resistance, and cure the patient.
★ There is a significant change in treatment recommendations in this update of the BOP Clinical Practice Guidelines on the Management of TB:

→ With rare exceptions, TB treatment is to be provided DAILY throughout therapy. Intermittent treatment (i.e., twice weekly therapy) is NOT recommended.
★ Any deviations to the standard regimen are rarely indicated.

Recommended TB treatment regimens and drug doses are outlined in:
- Appendix 6a, Standard Tuberculosis Treatment Regimen – 6 months
- Appendix 6b, First-Line Tuberculosis Drug Doses
- Appendix 6c, Tuberculosis Treatment Regimens in Special Situations

The following principles should be adhered to when treating confirmed or suspected TB patients.

GENERAL PRINCIPLES

• Four-drug DAILY therapy is routinely recommended initially for all inmates with a clinical or laboratory diagnosis of TB disease. Standard 4-drug “RIPE” treatment consists of rifampin, isoniazid, pyrazinamide, ethambutol plus vitamin B6 (pyridoxine).

• Never treat active TB with a single drug.

• Never add a single drug to a failing TB treatment regimen.

• All TB medications should be administered by directly observed therapy (DOT) to ensure adherence to the prescribed treatment regimen and reduce the emergence of resistant disease.

• DOT means watching the inmate swallow each dose of TB medication.
• **Seek expert consultation.** A physician consultant with expertise in TB treatment should be consulted for any of the following TB cases:
  - Failure of sputum cultures to convert to negative, following two months of therapy.
  - Resistance to rifampin, with or without resistance to other drugs.
  - HIV co-infection, drug intolerance, pregnancy, or other situations requiring deviation from a standard treatment regimen.
  - **Expert TB medical consultation can be obtained through the Central Office Infection Prevention and Control Program.**

**STANDARD TUBERCULOSIS TREATMENT REGIMEN**

| ★ These guidelines have been changed to indicate that treatment should be **daily** throughout, unless there are contraindications to daily treatment—such as renal insufficiency. |
| ★ Standard TB treatment occurs in two phases, the **initial phase** and the **continuation phase**, as outlined in **Appendix 6a**. |
| ★ Completion of TB treatment phases is based on counting the total number of doses ingested, and not the time elapsed since treatment started. |

**INITIAL PHASE (“RIPE” TREATMENT)**

• The initial phase consists of 8 weeks (56 daily doses) of rifampin (RIF), isoniazid (INH), pyrazinamide (PZA), and ethambutol (EMB), and is commonly referred to as “RIPE” treatment.

• The initial use of four drugs is essential to minimizing the risk of further development of drug resistance in inmates whose disease may be drug-resistant.

• All TB medications should be prescribed according to the inmate’s weight and adjusted appropriately with weight changes (weight can increase significantly after initiation of TB treatment).
  - **See Appendix 6b, First-Line Tuberculosis Drug Doses.**

• The initial phase is completed after completing all 56 recommended doses.
  - **Do not switch to the continuation phase until drug susceptibility tests confirm that the TB organism is sensitive to both INH and RIF and the inmate has received 56 daily doses of pyrazinamide.**
    - **Exception:** when an inmate’s cultures are negative at 8 weeks and the inmate is being treated for culture-negative TB.

**CONTINUATION PHASE**

• The initial phase is followed by the continuation phase, which consists of 18 weeks of RIF and INH administered daily (126 counted doses).
SPECIAL SITUATIONS IN TREATING ACTIVE TB

Modifications to the standard treatment regimen may be necessary in certain special situations, as outlined below.

➤ The treatment recommendations in the special situations discussed below are summarized in Appendix 6c.

CULTURE-NEGATIVE PULMONARY TB

Inmates with CXR evidence of active TB (with or without symptoms), a positive TST (in this case > 5mm) or IGRA, and negative AFB smears may be started on standard RIPE treatment for active TB.

➤ Expert review of chest radiographs should be obtained to determine whether the patient’s CXR shows evidence of active TB.

• If after starting on treatment all AFB cultures are negative, then a CXR is repeated after 8 weeks of daily RIPE treatment. The CXR request should specify request for a comparison with the initial CXR to assess for radiographic improvement.

➤ IF CXR/CLINICAL IMPROVEMENT ➔ INDICATIVE OF CULTURE NEGATIVE TB

If the CXR shows improvement or the patient shows symptomatic improvement on RIPE treatment, then this is considered to be diagnostic for culture-negative pulmonary TB. The PZA and EMB should be discontinued, and the INH and RIF should be continued for an additional 8 weeks.

➤ In other words, treatment for culture negative TB consists of an 8-week (56-dose) initial (“RIPE”) phase and an 8-week (56-dose) continuation phase of RIF and INH.

EXCEPTION: In the case of culture-negative pulmonary TB with HIV infection, or cavitation on CXR, the continuation phase of treatment (RIF and INH) should be extended to 18 weeks following the initial 8 weeks of RIPE treatment.

➤ IF NO CXR IMPROVEMENT ➔ CONSIDERED COMPLETE LTBI TREATMENT

If after 8 weeks there is no improvement in the CXR, then RIPE treatment is discontinued. The 8 weeks of RIPE treatment is considered to be complete treatment of latent TB infection (equivalent to 9 months INH) and the inmate should be coded in BEMR to indicate that.

Culture-negative pulmonary TB is considered to be a form of active TB and is reportable to the health department.

EXTRAPULMONARY TB

Extrapulmonary TB is generally treated using the same drug regimens as pulmonary TB. Treatment is generally extended for bone and joint disease (6 to 9 months) and TB meningitis (9 to 12 months), with the duration of treatment determined individually, based upon clinical response. Serial bacteriologic evaluations may be limited by disease location; therefore, treatment response must be judged on the basis of clinical and/or radiographic findings.
Inmates with a diagnosis of extrapulmonary TB should always be assessed for evidence of pulmonary TB, including sputum for AFB.

**HIV Co-Infection**

HIV infection significantly increases the risk of progression from latent to active TB disease. The CD4 cell count influences both the frequency and severity of active TB disease. Active TB also negatively affects HIV disease. It may be associated with a higher HIV viral load and more rapid progression of HIV disease.

Active pulmonary or extrapulmonary TB disease in HIV-infected inmates requires prompt initiation of TB treatment. Management of HIV-related tuberculosis is complex and requires consultation from experts in the management of both HIV disease and tuberculosis. The treatment of active TB disease in HIV-infected patients should follow the general principles guiding treatment for individuals without HIV.

- **All HIV-infected patients taking antiretroviral therapy (ART)** with the diagnosis of active TB should be started on TB treatment immediately, while continuing ART.

- **If the HIV-infected patient is not yet on ART**, it should be initiated under the following guidelines:
  - In patients with CD4 counts < 50 cells/mm$^3$, ART should be initiated within 2 weeks of starting TB treatment.
  - In patients with CD4 counts ≥ 50 cells/mm$^3$ who present with clinical disease of major severity, as indicated by clinical evaluation (including low Karnofsky score, low body mass index, low hemoglobin, low albumin, organ system dysfunction, or extent of disease), ART should be initiated within 2 to 4 weeks of starting TB treatment.
  - In patients with CD4 counts ≥ 50 cells/mm$^3$ who do not have severe clinical disease, ART can be delayed beyond 2 to 4 weeks of starting TB therapy, but should be started within 8 to 12 weeks of TB therapy initiation.

**COMBINING ART AND TB REGIMENS:** Despite pharmacokinetic drug interactions, a rifamycin (rifampin or rifabutin) should be included in TB regimens for patients receiving ART, with dosage adjustment if necessary. ART regimens should be assessed with particular attention to potential pharmacokinetic interactions with rifamycins. The patient’s regimen may need to be modified to permit use of the optimal TB treatment regimen.

- Use only rifabutin with protease inhibitors.
- If rifampin is used:
  - Efavirenz-based regimens have the least drug interactions.
  - If raltegravir is used, increase dose to 800mg twice daily.
  - If dolutegravir is used, increase dose to 50mg twice daily. Avoid if INSTI resistance is present.

**Immune Reconstitution/Paradoxical Reaction:** The term *immune reconstitution inflammatory syndrome* (IRIS) describes a collection of inflammatory disorders associated with paradoxical worsening of preexisting infectious processes following the initiation of ART in HIV-infected individuals. Preexisting infections in individuals with IRIS may have been previously diagnosed and treated, or they may be subclinical and later unmasked by the host’s regained capacity to mount an inflammatory response.

- This inflammatory reaction is usually self-limited, especially if the preexisting infection is effectively treated. However, long-term sequelae and fatal outcomes may rarely occur, particularly when neurologic structures are involved.
- Although it is reasonable to perform studies looking for unmasked subclinical opportunistic infection, the diagnosis of IRIS is generally one of exclusion. Investigations to rule out the possibility of drug reaction, patient noncompliance, persistently active infection and/or drug resistance are usually warranted before concluding that IRIS is present.
- Most patients with IRIS develop symptoms within one week to a few months after the initiation of ART. Treatment for the underlying pathogen should generally be started or continued in patients who develop IRIS. Corticosteroids or NSAIDS may help decrease the inflammatory response in some patients with IRIS. The decision to use corticosteroids should be individualized and should take into account the risks of therapy.

### Cavitary TB with Positive Cultures at Two Months

Very high rates of relapse have been reported in patients who present initially with cavitation on chest radiograph and whose sputum cultures remain positive after two months of treatment. Therefore, it is recommended that the continuation phase (RIF and INH) in such patients be extended an additional three months, for a total of nine months of treatment.

### Renal Insufficiency and End-Stage Renal Disease

Renal insufficiency complicates the management of TB because some anti-tuberculosis medications are cleared by the kidneys. Management may be further complicated by the removal of some anti-tuberculosis agents via hemodialysis.

For patients with a creatinine clearance of <30 ml/minute or who are on renal dialysis, the alterations in dosing and frequency outlined in Appendix 6b should be utilized. For patients on hemodialysis, medications should be given 3 times per week—after dialysis.

### Drug Resistance and Intolerance

Consultation with a TB expert and the Central Office Infection Prevention and Control Program should be sought when treating TB that is complicated by either drug resistance or intolerance.

- *Generally recommended treatment regimens for drug resistance or intolerance are outlined in Appendix 6c.*

Multiple drug resistant TB (MDR-TB), defined as resistance to at least isoniazid and rifampin, can generally be treated successfully with a prolonged treatment regimen if managed appropriately. In some parts of the world, extensively drug resistant TB (XDR-TB) is
increasingly common. XDR-TB is defined as resistance to isoniazid and rifampin plus resistance to any fluoroquinolone and at least one of three injectable second-line drugs (i.e., amikacin, kanamycin, or capreomycin). XDR-TB, an emerging global pathogen associated with very poor treatment outcomes, requires expert consultation.

**MONITORING TREATMENT**

All inmates with active TB disease should be monitored at least monthly to evaluate the clinical response to therapy and to monitor side effects of medications.

- **Baseline laboratory studies, TB medication regimens, and monitoring of adverse reactions** should be in accordance with parameters outlined in Appendix 4, TB Case Management Checklist.

- **Document monitoring of TB cases utilizing the Active TB Monitoring in BEMR.**

**CLINICIAN EVALUATION**

- At a minimum, patients on treatment for active TB disease should be evaluated by a physician or qualified mid-level provider (with physician review) at initiation of treatment; at ~2 months of treatment; if signs and symptoms of adverse reactions or lack of clinical response; whenever treatment is interrupted; at treatment completion; and monthly throughout treatment if drug resistant TB, drug intolerance or HIV co-infection.
- Inmates with baseline elevations of liver transaminases or other complicating medical conditions should be followed closely.

**BASELINE LABS**

Includes HIV test, ALT/AST, bilirubin and uric acid, and a complete CBC and platelets. HBsAg and anti-HCV should be obtained if risk factors for viral hepatitis and no previous test in the BOP. A fasting serum glucose should be obtained because of the increased risk of active TB associated with diabetes mellitus.

**BASELINE VISION TESTS**

Optic neuritis is a rare adverse effect of ethambutol. The risk of optic toxicity is higher at higher doses given daily. Start with EMB 15 mg/kg to reduce the risk of ocular toxicity. The use of 25 mg/kg should be reserved for patients requiring retreatment or drug resistant TB.

- A Snellen (visual acuity) and Ishihara (red-green color vision test) should be performed prior to initiating treatment with ethambutol.
MONITORING FOR ADVERSE REACTIONS / CLINICAL RESPONSE TO TREATMENT

Monitoring and documentation of signs and symptoms of clinical response and adverse reactions should be conducted weekly initially and then monthly in a BEMR Active TB Monitoring Clinical Encounter.

BACTERIOLOGIC CONVERSION

- See Appendix 5, Sputum Collection Procedures. Sputum should be obtained in an airborne infection isolation room (AIIR). Lacking an AIIR, another option is to obtain these specimens outdoors if this can be accomplished discretely. If necessary, sputum should be induced.

  • **Inmates who AFB sputum smear positive initially should have 3 sputum samples obtained weekly until AFB smears convert to negative (3 consecutive negative smears).**

  • **Inmates with sputum cultures positive for M. tuberculosis should each month have three consecutive adequate sputum cultures for AFB** (obtained 8 hours apart, including one early morning specimen), until cultures convert to negative (three consecutive negative cultures).

  • **Sputum cultures positive for M. tuberculosis after two months of drug treatment may indicate ineffective therapy.**

    ▶ Repeat drug sensitivities should be obtained for those patients who fail to convert sputum cultures to negative within two months.

    ▶ Inmates with TB disease who do not respond to standard drug therapy by the end of two months of treatment may be nonadherent to their medication regimen, or they may have malabsorption, drug interactions, or other problems resulting in subtherapeutic serum drug levels. Persons with chronic gastrointestinal disease (e.g., Crohn’s disease or HIV-related diarrhea) are particularly at risk for drug treatment failure.

    ▶ Serum drug levels should be obtained (in consultation with the Central Office Infection Prevention and Control program) to document the adequacy of medication delivery for inmates with known malabsorption or who fail to respond to TB treatment.

RADIOGRAPHIC MONITORING

- CXRs should be obtained at baseline and at the completion of therapy. The purpose of the CXR at the completion of treatment is to serve as a baseline for future comparisons.

- CXRs are only obtained during treatment if clinically indicated.

- Patients with suspected pulmonary TB and negative sputum cultures should have a repeat CXR after 8 weeks of treatment (with comparison to prior CXR). CXR improvement is indicative of culture-negative TB. (See Culture Negative Pulmonary TB in Section 6.)

MONITORING FOR DRUG-INDUCED HEPATITIS

Three of the first-line TB medications (RIF, INH and PZA) can cause drug-induced liver injury. Liver transaminases should be obtained at baseline. Symptom screening for hepatitis (nausea, vomiting, abdominal pain, fatigue) should be reviewed at least monthly, and medications generally should be stopped if they occur.

▶ **Monthly monitoring of liver enzymes should be conducted for inmates with risk factors for hepatotoxicity.** (See Appendix 4, step 13.)
• Moderate asymptomatic increases in AST or ALT levels occur in nearly 20% of patients treated with the standard 4-drug RIPE regimen and do not indicate hepatic injury.

• In the absence of symptoms, therapy should not be altered because of these modest asymptomatic AST or ALT elevations, but the frequency of clinical and laboratory monitoring should be increased.

• However, if at any point, liver transaminases are greater than 3 times normal (with symptoms) or greater than 5 times normal (without symptoms), hepatotoxic drugs should be stopped immediately and the patient should be evaluated carefully. Liver function studies should be measured. Once the liver enzymes return to normal, the person should be rechallenged with TB medications, after consultation with a TB expert.

**MONITORING VISUAL ACUITY (WHILE ON ETHAMBUTOL)**

For patients treated with ethambutol, visual acuity (Snellen) and red-green color vision (Ishihara) should be assessed at baseline, and monthly thereafter. For patients on prolonged treatment with ethambutol, supplementary optometry evaluations are indicated every three months. Patients with visual changes should have ethambutol stopped and be evaluated by an ophthalmologist.

**MONITORING FOR OTHER TB DRUG TOXICITIES**

• Baseline complete blood count, platelets, and uric acid should be obtained in addition to LFTs.

• Thrombocytopenia is a rare toxicity associated with rifampin.

• Elevated uric acid can occur with pyrazinamide, but rarely necessitates a change in regimen.

• Baseline and monthly creatinine and audiograms are indicated for inmates receiving streptomycin or other aminoglycosides, due to the risk of nephrotoxicity and ototoxicity.
7. CONTACT INVESTIGATIONS

STEPWISE PROCEDURE FOR CONTACT INVESTIGATION

GOALS: The goals of a TB contact investigation are to:

1) identify other active cases of TB (rare); and

2) Identify and completely treat individuals with new LTBI, particularly those at high risk for developing the disease.

The identification of a pulmonary or laryngeal TB case in a correctional facility should always provoke a rapid response because of the potential for widespread TB transmission. Numerous outbreaks of TB have been reported in prisons and jails, especially among HIV-infected inmates. A prompt public health response can prevent a TB outbreak.

MULTIDISCIPLINARY APPROACH: The decisions involved in planning and prioritizing contact investigations in correctional facilities are seldom clear-cut and benefit from multi-disciplinary team input. Shortly after the case is diagnosed, the Clinical Director and the Health Services Administrator should convene a team of professionals who will plan the contact investigation. Ideally, the team should include staff from infection control, medical, nursing, and custody. Large contact investigations should also involve Regional and Central Office HSD staff. Generally, the local health department should also be consulted during contact investigations.

A stepwise approach to managing a TB contact investigation is outlined in Appendix 8, Tuberculosis Contact Investigation Checklist. It is recommended that the contact investigation team review and utilize this checklist as a guide when planning and implementing a TB contact investigation.

TRANSMISSION FACTORS

The characteristics of the index case, the contacts, and the exposure all affect the likelihood of TB transmission.

1. INDEX CASE CHARACTERISTICS: When an index case has either cavitation on CXR or AFB smear-positive respiratory specimens, there is a much higher risk of TB transmission than if neither of those characteristics is present. If the inmate has been coughing for a prolonged period of time, there is also a higher risk of TB transmission.

2. CONTACT CHARACTERISTICS:

   Immunosuppression: HIV infection is the greatest single risk factor for progression to TB disease in infected persons. Therefore, HIV-infected contacts should receive the highest priority for evaluation, even if they had shorter duration of exposure than other contacts. Persons receiving prolonged therapy with corticosteroids or other immunosuppressive agents should also be considered high priority for investigation.

   Groups of contacts who are likely to benefit from a full course of presumptive treatment (regardless of TST results) are those with HIV infection, those taking immunosuppressive therapy for organ transplantation, and those taking anti-TNF-alpha drugs.
► **Age:** Young children (age ≤ 4) are at high risk for development of active TB disease and should be evaluated promptly. When an inmate identifies a child (age ≤ 4) as a community contact, a health department referral should be made immediately because of the potentially life-threatening consequences of undetected TB in a young child.

3. **Exposure Characteristics:**

► **Air Volume:** The volume of air shared between an infectious TB patient and susceptible contacts is an important determinant in the risk of TB transmission. The larger the air space, the more infectious particles are distributed and the less likely they are to be inhaled.

► **Ventilation:** Ventilation is a key factor in the risk of airborne transmission of TB.

- Exposures in confined air systems with little or no ventilation have been associated with increased TB transmission.
- The spread of airborne infection extends to all space sharing the same air. Thus, if air circulates from the room occupied by an infectious patient into other rooms, the occupants of these other rooms will also be exposed.

► **Duration of Exposure:** Even though transmission of TB can occur from a brief exposure, the likelihood of infection from exposure to an infectious patient is related to the frequency and duration of exposure. It is impossible to know what constitutes a significant duration of exposure for a given contact in a particular environment before conducting contact screening. Priority should be given to inmates and employees who sustained the most exposure to the index case.

**Decision to Initiate a Contact Investigation**

The decision to initiate a contact investigation should be based on the characteristics of the presenting TB case. Contact investigations should be conducted for index cases in the following circumstances:

1. **Suspected or confirmed pulmonary, laryngeal, or pleural TB and …**
   - Cavitary disease on CXR  **OR**
   - Positive AFB smears (of sputum or other respiratory specimens)

2. **Suspected or confirmed pulmonary (non-cavitary) or pleural TB, with AFB-negative smears** (of sputum or other respiratory specimens). A more limited investigation should be conducted for symptomatic AFB smear-negative cases.

Contact investigations are generally not indicated for extrapulmonary TB cases (except for laryngeal and pleural) without pulmonary involvement.

► *If the patient can produce sputum, it should always be collected and used to guide the investigation. However, in some patients with pulmonary TB, it may not be possible to collect sputum samples. In such cases, other types of respiratory specimens (e.g., those from bronchoscopy) may be collected and tested as a surrogate for sputum in determining the need for and priority of the contact investigation.*
PRIORITIZING AND STRUCTURING THE CONTACT INVESTIGATION

Unfortunately, there is no simple formula for deciding which contacts to screen in a correctional facility contact investigation. However, there are several basic principles to guide the contact investigation team in making decisions about structuring the investigation:

- Promptly screen and initiate treatment for LTBI for all close contacts infected with HIV, taking immunosuppressive therapy for organ transplantation, or taking TNF-α antagonists.
- Screen an identified group of contacts who are at highest risk of being exposed to infection (i.e., greatest duration of exposure, or concentrated exposure in a confined space).
- Calculate the infection rate for each group of exposed persons (i.e., cell-mates, dorm-mates, co-workers, and exposed employees working in a dorm).
- Decide how to structure the investigation based on the infection rates.

DECIDING WHEN AND WHERE TO EXPAND THE INVESTIGATION

Focus should be placed on identifying the highest risk contacts, completely screening them, and providing a full course of treatment of LTBI for those who are infected.

- In general, avoid mass screening of everyone who has had any contact with the index case.

If there is no evidence of transmission, then usually the investigation should be stopped. If there is evidence of transmission, the investigation is expanded incrementally to groups with less exposure, until there is a screened group with minimal or no evidence of transmission.

There is no formula for determining if an infection rate is “significant” and therefore merits expanding the investigation. The unique circumstances surrounding an investigation must be taken into account and evaluated in relation to calculated infection rates. Ideally, decisions about structuring the contact investigation should be made by the contact investigation team as a whole, seeking expert opinion from the Regional/Central Office and the state or local health department, as needed.

Sometimes, it is necessary to first screen a “convenience sample.” For example, in jail investigations, many contacts may have already been released, and the only easily accessible contacts available for screening are those who remain incarcerated.

Rarely is an index case so infectious that wide-scale expansion of the contact investigation is necessary. Wide-scale investigations divert attention away from the high priority activities needed to interrupt TB transmission in the facility—i.e., complete screening and appropriate treatment of the contacts who are most likely to have become infected.
MEDICAL EVALUATION OF CONTACTS

The medical evaluation required depends on the contact’s immune status and TST results.

- HIV testing is generally recommended for inmate contacts with unknown HIV status.

1. **All contacts should be interviewed for symptoms of active TB and to encourage HIV testing (if status is unknown).**

   - Symptomatic inmate contacts should receive a CXR and complete medical evaluation, regardless of TST status. Symptomatic inmates should be isolated in an AIIR if CXR or clinical findings suggest contagious TB.
   
   - Asymptomatic inmate contacts do not require isolation.

2. **Close contacts of infectious TB cases who are HIV seropositive, taking immunosuppressive therapy for organ transplantation, or taking TNF-alpha antagonists** should generally initiate a complete course of treatment for LTBI—after ruling out active TB by symptom review and CXR.

   - Treatment should be initiated regardless of TST results, even for those with a history of prior treatment for LTBI or active disease, because of the possibility of re-infection.
   
   - Those with a history of a negative TST should have a TST placed at baseline and again in 8–10 weeks. The results of the TST, while not affecting treatment decisions, provide important information for the overall contact investigation.

3. **Inmate contacts with a prior negative TST, and who are HIV-seronegative, require a TST.**

   - Mandatory tuberculin skin testing of all previously TST-negative inmate contacts should be conducted at baseline (unless previously tested within 1–3 months of exposure) and repeated 8–10 weeks from the last contact with the source case.
   
   - TST convertors (TST ≥ 5mm) should be prescribed treatment for LTBI unless medically contraindicated.
   
   - If inmate contacts refuse medically indicated treatment of LTBI, they should be monitored with a CXR and symptom screen:
     
     - every 6 months for 2 years, if HIV seronegative
     
     - every 6 months indefinitely, if HIV-seropositive and CD4 < 200 cells/mm³.

4. **Asymptomatic inmate contacts with a prior positive TST, and who are HIV-seronegative or whose HIV status is unknown, generally require no further follow-up.**

   - If HIV status is unknown, inmates should be tested for HIV infection.
8. INFECTION CONTROL MEASURES

EARLY DETECTION

The most important measure to prevent TB transmission in a correctional facility is to maintain a high index of suspicion for TB. Early identification and isolation of TB cases is critical to prevent further TB transmission.

- Most TB outbreaks reported from correctional facilities involve a highly infectious case of TB with a persistent cough that remains undetected for a prolonged period of time.
- It is the responsibility of all correctional facility staff to identify inmates with a chronic cough and refer them to Health Services.

INMATE SCREENING AND COUNSELING: All inmates should be screened for TB symptoms at intake. They should be counseled at orientation—and during clinical evaluations when appropriate—to recognize and promptly report possible symptoms of TB disease. They should be encouraged to participate in baseline and annual skin-testing to screen for TB infection. If diagnosed with either TB disease or LTBI, inmates should be advised about the importance of completing their treatment. Inmates should be counseled that certain risks and conditions—such as HIV infection, taking anti-TNF alpha drugs, diabetes, chronic renal failure, injection drug use history, and close contact with someone who is sick with infectious TB—all pose a greater risk for getting TB disease if they become exposed to it.

AIRBORNE INFECTION ISOLATION

- INITIATION:
  - Inmates with suspected TB should be promptly isolated in an airborne infection isolation room (AIIR)—formerly known as a negative pressure isolation room (NPIR). In accordance with CDC guidelines, the room should have been validated within the previous year.
  - Prior to placing inmate in an AIIR, assure that there is negative pressure in the room by performing a “tissue test.” Place a singly-ply tissue under the closed door of the room to see if it is drawn under the door, thereby demonstrating negative pressure.
  - The inmate should be instructed to cover his or her mouth when coughing or sneezing.
  - Inmates should remain isolated until they meet the criteria for discontinuation of isolation.
  - See Appendix 7, for criteria for discontinuation of airborne infection isolation.

- RESPIRATORY PROTECTION: Inmates should be managed using airborne precautions and personal respiratory protection designed to prevent transmission of *M. tuberculosis*.
  - All persons entering an AIIR or transporting an infectious patient in a closed space should wear appropriate respiratory protection, in accordance with BOP policy and OSHA recommendations.
► The minimal acceptable form of respiratory protection to protect against TB transmission is an N-95 respirator mask.
► Respirators should only be utilized in the context of a fit-tested OSHA-compatible respiratory protection program, including medical evaluation, fit-testing, and training.

- **Monitoring Inmates in Isolation:** Inmates should be seen by a health care provider daily while isolated, with the visit documented in the medical record.

- **Isolation Discontinuation:**
  ► Inmates with suspected TB should remain in airborne infection isolation until they meet criteria for discontinuation of isolation (see Appendix 7).
  ► Assess weekly to determine if the inmate meets criteria for discontinuation of isolation.
  ► If isolation extends beyond 14 days, hold weekly case conferences to assess plan for assuring that isolation is discontinued as soon as possible.

- **Clearance Time for AIIRs:** The room should be appropriately purged of airborne contaminants before the room is used to house another inmate or is occupied without the use of protective respiratory protection. BOP AIIRs should not be entered without respiratory protection until two hours after they have been exited by a patient with an airborne infectious disease.

**Transport**

- When a potentially infectious inmate is being transported outside an AIIR, the inmate should be instructed to wear a surgical mask.
- Movement of the inmate should be limited to those situations where movement is required for medical or security purposes.
- If the TB suspect is in a confined space (e.g., a vehicle), others in the vehicle should be fit-tested and wear an N-95 respirator mask.
- The ventilation system for the vehicle should bring in as much outdoor air as possible, and the system should be set to nonrecirculating.
9. Discharge Planning

Discharge planning begins as soon as a suspected case of active TB is identified. Inmates should be placed on Medical Hold (in SENTRY and BEMR) to prevent transfer to another facility during TB diagnosis and treatment. Inmates receiving treatment for LTBI or TB disease should have their treatment plan coordinated with community providers by the time of release to help ensure continuity of care and to maintain public health.

☑ Check the Projected Release Date. If the date precedes the anticipated date of TB treatment completion, then begin discharge planning immediately.

☑ Determine where the inmate is likely to go upon release, e.g., deportation, return to home, etc.

☑ The BP-A0665 form serves as both a TB case report form and as referral form. All available information about the TB diagnosis and treatment should be recorded on the form.

☑ All inmates with active TB disease should have a specific plan for continuing treatment via an international referral program or state health department.

☑ For inmates who will be deported. CURE-TB and TB-Net are U.S.-based referral programs that assist mobile patients to access and complete TB treatment. These agencies generally conduct telephone interviews to refer inmates for care after release. Utilize the completed BP-A0665 form for referrals to CURE-TB and TB-Net.

→ CURE-TB, operated by the San Diego County Health and Human Services Agency TB Control Program, focuses on patients crossing the U.S.-Mexico border. TB referrals can be made through CURE-TB. Information available at http://www.sandiegocounty.gov/hhsa/programs/phs/cure_tb/

→ TB-Net, operated by the nonprofit Migrant Clinicians Network in Austin, Texas, provides international referrals throughout the world. Information available at http://www.migrantclinician.org/services/network/tbnet.html

☑ Inmates who will be released in the United States should have referrals made to state health departments where your BOP facility is located. The health department is responsible for assuring interstate notifications.

→ For a list of state TB programs, see the National TB Controller’s Association website, “State, Big City, and Territory TB Contacts” at: http://www.tbcontrollers.org/community/statecityterritory/#.VhOpKivjJ5o

☑ Provide counseling to ensure that the inmate understands the importance of adherence to treatment and receives specific instructions for seeking care upon release.

☑ Supply TB medications to the inmate in accordance with BOP policy.
10. TB PROGRAM MANAGEMENT

The Clinical Director and Health Services Administrator should work collaboratively to ensure that BOP policy, these Management of Tuberculosis Clinical Practice Guidelines, and the requirements of the OSHA Respiratory Protection Standard (1910.134) are fully implemented.

TB CASE MANAGEMENT

→ See Appendix 4, TB Case Management Checklis for a detailed overview of case management responsibilities.

Each suspected or confirmed case of tuberculosis shall be assigned a TB Case Manager (usually the Infection Prevention and Control Coordinator). The role of the TB Case Manager includes the following:

• Assure that the TB case/suspect is appropriately reported to the Regional and Central Offices and to the local health department.
• Track the diagnostic work-up.
• Assure that the inmate is appropriately isolated, if indicated.
  → See Appendix 7, for criteria for discontinuation of airborne infection isolation.
  ▶ Assure that the inmate is not released from isolation and returned to general population until he or she has met the criteria for release from isolation.
  ▶ Assure that inmates are released from isolation as soon as criteria is met.
• Assure that the inmate is placed on Medical Hold (in both BEMR and SENTRY) until TB treatment completed or TB is ruled out.
• Coordinate with the local pharmacist to assure that drug treatment/dosing is appropriate.
• Communicate with the health department and hospital infection control practitioner.
• Assure that appropriate monitoring occurs—including laboratory, monthly symptom screen, visual acuity/color vision screening while on ethambutol, monthly sputum specimens, etc.
• Assure that there is regular assessment with compliance with treatment. At least monthly, count and summarize the number of doses ingested for each treatment phase.
• Coordinate the TB contact investigation, if indicated.
• Immediately start release planning if the inmate’s projected release date is prior to the projected TB treatment completion date or if the projected release date is unknown.
  → See Section 9, Discharge Planning.
• Ensure that health problem codes are updated appropriately in the electronic medical record.
• Regularly update the BP-A0665 form with new information regarding the TB case, and post the updates in the electronic medical record.
  ▶ A final version of the report shall be completed, summarizing the outcome and filed in the electronic medical record so that the history of the diagnostic work-up and treatment is accessible for future reference.
Tuberculosis Exposure Control Plan

Each facility will develop a TB Exposure Control Plan that defines facility-specific procedures to fulfill policy and regulatory requirements shall be completed and updated annually. An optional template TB Exposure Control Plan can be obtained on the Sallyport/Health Services Division/Infectious Diseases site. The facility’s Infection Prevention and Control Committee shall review at least annually the facility’s compliance with its Tuberculosis Exposure Control Plan.

**Particular attention should be focused on ensuring the following:**

- TB symptom screening at intake is occurring according to BOP policy.
- TB suspects are isolated and evaluated for contagious TB.
- All inmates with TB disease are treated in accordance with recommended guidelines.
- Contacts to TB cases receive appropriate evaluation and follow-up.
- Annual tuberculin skin testing of inmates is timely and data are evaluated, to detect unrecognized transmission of *M. tuberculosis*.
- Inmates are treated for LTBI in accordance with recommended guidelines.
- TB case reports and referrals are made to health authorities as appropriate.

Program Evaluation

*Strategic measures should be monitored in order to assess the effectiveness of the TB program, such as the following:*

- Annual TST conversion rate (inmates and staff).
- Completion of treatment for latent TB infection.
DEFINITIONS

NOTE: Terms used in "SMALL CAPS" within a definition are listed elsewhere in this section with their own definitions.

ACID-FAST BACILLI (AFB) are bacteria that retain certain dyes after being washed in an acid solution. Most acid-fast bacilli are mycobacteria. When AFB are seen on a stained SMEAR of sputum or other clinical specimen, a diagnosis of TB should be suspected; however, the diagnosis of TB is not confirmed until a culture is grown and identified as M. TUBERCULOSIS.

AIRBORNE EXPOSURE is the condition of being subjected to an infectious agent that could have a harmful effect if airborne transmission occurs. A person exposed to M. TUBERCULOSIS does not necessarily become infected.

AIRBORNE PRECAUTIONS are protective measures used for patients/inmates and situations to prevent the spread of infections that can be transmitted by airborne contact with infectious agents that remain suspended in the air when indoors over a period of time. Precautions include the wearing of appropriate personal respiratory protection (i.e., N-95 respirator) for persons who come in direct contact with infectious airspace; the isolation of infectious patients/inmates in a private room with monitored, negative air pressure; and the implementation of necessary engineering controls to inform, direct, and protect persons entering the isolation rooms.

AIRBORNE INFECTION ISOLATION ROOMS (AIIR) are rooms designed to prevent AIRBORNE EXPOSURE. Formerly called a NEGATIVE PRESSURE ISOLATION ROOM (NPIR), an AIIR is a single-occupancy, patient-care room used to isolate persons with suspected or confirmed infectious TB disease. Environmental factors are controlled in AIIRs to minimize the transmission of infectious agents that are usually spread from person-to-person by droplet nuclei associated with coughing or aerosolization of contaminated fluids. AIIRs should provide negative pressure in the room (so that air flows under the door gap into the room), an air flow rate of 6–12 ACH, and direct exhaust of air from the room to the outside of the building or recirculation of air through a HEPA filter.

ANERGY is the inability of a person to react to skin test antigens (even if the person is infected with the organisms tested) because of immunosuppression.

ANTIGENS are substances that can produce an immune response, especially the production of antibodies.

ANTI-TNF ALPHA DRUGS (tumor necrosing factor alpha antagonists) are immunosuppressive drugs utilized for treatment of inflammatory conditions such as psoriasis and rheumatoid arthritis. They have been demonstrated to increase the likelihood of TB disease in those infected with TB who start on those drugs.

See the right-hand column in Appendix 1 for a list of these drugs.

BCG (BACILLUS CALMETTE-GUERIN) are vaccinations used in many parts of the world to prevent development of TB disease.

BOOSTER PHENOMENON occurs when persons (especially older adults) many years after initial infection with M. TUBERCULOSIS have a negative reaction to an initial skin test, followed by a positive reaction to a subsequent skin test. The second positive reaction is caused by a boosted immune response, indicating LATENT TB INFECTION (LTBI).
CLEARANCE TIME is the time between the discharge of an inmate isolated for airborne precautions in an AIIR and the arrival of another inmate or other person(s) who will occupy the room without the use of airborne precautions.

CONTACT is a person who has shared the same air with a person who has infectious TB for a sufficient amount of time to allow possible transmission of *M. TUBERCULOSIS*.

CULTURE is the process of growing bacteria in the laboratory so that organisms can be identified.

DELAYED-TYPE HYPERSENSITIVITY REACTION is a cellular immunologic response caused by lymphokines released from T cells that have been sensitized by prior infection with a specific antigen.

DIRECTLY OBSERVED THERAPY (DOT) is the practice of administering a unit dose of TB medication to an inmate by a clinician, nurse, pharmacist, or specially trained staff member who directly observes ingestion of each dose.

DRUG SUSCEPTIBILITY TESTS are the laboratory tests that determine whether the TB bacteria cultured from a patient are susceptible or resistant to various anti-tuberculosis drugs.

IGRA is the acronym for interferon-gamma release assay, a type of whole-blood test that can aid in diagnosing *M. TUBERCULOSIS* infection.

See the discussion of Interferon-Gamma Release Assays in Section 3, Screening.

IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME (IRIS) describes a collection of inflammatory disorders associated with paradoxical worsening of preexisting infectious processes following the initiation of ART in HIV-infected individuals.

See discussion under HIV Coinfection in Section 6.

INDEX CASE is the initial person with suspected or confirmed infectious TB who may have been in contact with other persons, while sharing the same air space for a sufficient amount of time to allow possible transmission of *M. TUBERCULOSIS*. This person is sometimes called the SOURCE CASE.

INTRADERMAL is within the layers of skin.

LATENT TUBERCULOSIS INFECTION (LTBI) is a condition in which a relatively small number of living tubercle bacilli (*M. TUBERCULOSIS*) are present in the body, but are not multiplying or causing clinically active disease. Although persons with LTBI usually have positive tuberculin tests, they have no symptoms or other objective evidence of TB disease and are not infectious to others. Persons with LTBI, however, have a lifelong risk for developing active TB disease.

MANTOUX METHOD is the most reliable method of tuberculin skin testing, involving the intradermal injection of PPD-tuberculin into the forearm with a needle and syringe.

MTB is an abbreviation for *MYCOBACTERIUM TUBERCULOSIS*

MULTI-DRUG RESISTANT TB (MDR-TB) is active TB caused by *M. TUBERCULOSIS* organisms that are resistant to at least isoniazid and rifampin, with or without resistance to other drugs.
**Mycobacterium Tuberculosis (MTB) Complex** is a term frequently seen on laboratory reports for positive AFB cultures. The complex includes *M. tuberculosis* and four other TB-causing mycobacteria: *M. bovis*, *M. africanum*, *M. canetti*, and *M. microti*. A report indicating MTB complex is generally considered to be confirmation of tuberculosis and an indication for treatment for TB disease.

**Mycobacterium Tuberculosis (M. tuberculosis)** is the mycobacterial species that is the primary cause of active TB disease in the United States.

**Negative Pressure Isolation Room (NPIR)** was the former nomenclature for a room designated for the isolation of patients with contagious TB disease, with adequate directional airflow, air exchanges, and exhaust. The new name is an Airborne Infection Isolation Room (AIIR).

**Nucleic Acid Amplification Tests (NAAT)**, also sometimes referred to as rapid tests or PCR tests, identify genetic material unique to MTB directly in clinical samples. Detecting *M. tuberculosis* (MTB) complex with traditional laboratory culture methods takes one to eight weeks; however, direct molecular methods using nucleic acid amplification can detect MTB genetic material directly from specimens within three to five hours.

**Personal Respiratory Protection** is the use of respirators to protect a person from the transmission of airborne infectious agents. Particulate respirators indicated for protection against *M. tuberculosis* are selected and worn, based on recommendations from the Centers for Disease Control and Prevention (CDC) and certification criteria from the National Institute for Occupational Safety and Health (NIOSH).

**Purified Protein Derivative (PPD) tuberculin** is the agent used for tuberculin skin testing (TST) to evaluate the likelihood that a person is infected with *M. tuberculosis*.

**Recent Convertor** is an individual who has a negative TST reaction that increases in reaction size by >10 millimeters (mm) within a period of two years; this is suggestive of recent infection with *M. tuberculosis*.

**RIPE** is an acronym for the standard, initial four-drug therapy: Rifampin, Isoniazid, Pyrazinamide, and Ethambutol.

**Smear (AFB Smear)** is the laboratory technique for visualizing mycobacteria. The specimen is smeared onto a slide and stained, then examined using a microscope. A large number of mycobacteria seen on an AFB smear from a person with TB usually indicates infectiousness. However, a positive smear is NOT diagnostic of TB because acid-fast organisms other than *M. tuberculosis* may be seen on an AFB smear.

**Surgical Mask** is a disposable paper type mask used to prevent respiratory secretions from the person wearing the mask from entering into the air. Surgical masks should be worn by known or suspected infectious TB patients during transport or awaiting isolation.

**Tuberculosis Disease** is a clinically active disease caused by *Mycobacterium Tuberculosis* which are sometimes referred to as tubercle bacilli. Symptoms of TB disease depend on the site of active disease. Pulmonary TB, the most common form of TB, is characterized by chronic cough, hemoptysis, and chest pain. General symptoms of TB include fever, chills, night sweats, malaise, loss of appetite, and weight loss.
**TST** is the acronym for tuberculin skin test.  
See discussion of the Tuberculin Skin Test in Section 3, Screening.

**TWO-STEP TESTING** is baseline tuberculin testing that, if negative, is repeated to reduce the future likelihood of mistaking a boosted reaction for a new infection with *M. TUBERCULOSIS*. If the initial baseline TST result is classified as negative, a second test is repeated one to three weeks later. If the reaction to the second test is positive, it represents a boosted reaction indicating old LATENT TB INFECTION. If the second test result is also negative, the person is classified as not infected with *M. TUBERCULOSIS*.

**XDR-TB** (extensively drug resistant TB) is defined as TB that is resistant to isoniazid and rifampin plus resistant to a fluoroquinolone and resistant to at least one of three second-line injectable drugs, i.e., capreomycin, kanamycin or amikacin. It is an emerging global pathogen associated with very poor treatment outcomes.
REFERENCES

TB AND CORRECTIONS


EPIDEMIOLOGY


DIAGNOSIS AND TREATMENT


Centers for Disease Control and Prevention. Notice to readers: revised definition of extensively drug-resistant tuberculosis. *MMWR.* 2006;55(43):1176. Available at: [http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5543a4.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5543a4.htm)

Centers for Disease Control and Prevention. Recommendations for the use of an isoniazid-rifapentine regimen for direct observation to treat latent *Mycobacterium tuberculosis* infection. *MMWR.* 2011;60(48):1650–1653. Available at: [http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6048a3.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6048a3.htm)


Centers for Disease Control and Prevention. Updated guidelines for the use of nucleic acid amplification tests in the diagnosis of tuberculosis. *MMWR.* 2009;58(01):7–10. Available at: [http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5801a3.htm?s_cid=mm5801a3_e](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5801a3.htm?s_cid=mm5801a3_e)


**INFECTION CONTROL AND CONTACT INVESTIGATIONS**


**DISCHARGE PLANNING**


### APPENDIX 1. TUBERCULOSIS RISK FACTORS

<table>
<thead>
<tr>
<th>Risk Factors for TB Infection</th>
<th>Risk Factors for TB Disease (If Infected)</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Close contacts to infectious TB cases</td>
<td>• HIV infected persons</td>
</tr>
<tr>
<td>• Foreign born from high-incidence countries*</td>
<td>• TST convertors/recently infected</td>
</tr>
<tr>
<td>• Injection drug users</td>
<td>• Fibrotic scarring on chest x-ray, consistent with old-healed TB</td>
</tr>
<tr>
<td>• Residents/employees of:</td>
<td>• Injection drug users</td>
</tr>
<tr>
<td>▶ Prisons and jails</td>
<td>• Certain clinical conditions:</td>
</tr>
<tr>
<td>▶ Long-term care facilities</td>
<td>▶ Organ transplant recipient</td>
</tr>
<tr>
<td>▶ Hospitals and long-term care facilities</td>
<td>▶ Immunosuppressant therapy (equivalent to 15 mg prednisone/day for 1 month)</td>
</tr>
<tr>
<td>▶ Homeless shelters</td>
<td>▶ Anti-TNF alpha therapy, for example:</td>
</tr>
<tr>
<td>• Mycobacteriology laboratory personnel</td>
<td>o infliximab (Remicade®),</td>
</tr>
<tr>
<td>• Children exposed to high-risk adults</td>
<td>o etanercept (Enbrel®),</td>
</tr>
<tr>
<td></td>
<td>o adalimumab (Humira®),</td>
</tr>
<tr>
<td></td>
<td>o certolizumab (Cimzia®)</td>
</tr>
<tr>
<td></td>
<td>o golimumab (Simponi®)</td>
</tr>
<tr>
<td></td>
<td>• Silicosis</td>
</tr>
<tr>
<td></td>
<td>• Diabetes mellitus</td>
</tr>
<tr>
<td></td>
<td>• Chronic renal failure</td>
</tr>
<tr>
<td></td>
<td>• Leukemia/lymphomas</td>
</tr>
<tr>
<td></td>
<td>• Carcinomas of head, neck, lung</td>
</tr>
<tr>
<td></td>
<td>• Underweight (&gt;10% under ideal weight)</td>
</tr>
<tr>
<td></td>
<td>• Gastrectomy/jejuno-ileal bypass</td>
</tr>
</tbody>
</table>

## APPENDIX 2. TUBERCULIN SKIN TESTING GUIDELINES

<table>
<thead>
<tr>
<th>SCREENING CRITERIA</th>
<th>TST negative inmates:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>• Upon incarceration within the BOP</td>
</tr>
<tr>
<td></td>
<td>➔ <strong>Exception:</strong> If an inmate is in holdover status with a short length of stay anticipated, and has documentation of a negative TST in the last year while incarcerated, then that TST is considered valid for screening purposes.</td>
</tr>
<tr>
<td></td>
<td>• Annually</td>
</tr>
<tr>
<td></td>
<td>• When TB is suspected</td>
</tr>
<tr>
<td></td>
<td>• As part of TB contact investigation</td>
</tr>
</tbody>
</table>

| PRIOR POSITIVE TST | A baseline tuberculin skin test (TST) should generally be obtained on all new intakes to the BOP—regardless of an inmate’s reported history of a prior positive TST—with the following exceptions: |
|--------------------|• prior documentation of positive TST while inmate was incarcerated within BOP |
|                    |• history of a severe TST reaction, e.g., swollen, blistering (vesiculated) reaction |
|                    |• credible history of treatment for LTBI (e.g., able to state place, duration, year treated). |

| PLACEMENT | • Specific training for placing and reading tests should be obtained. See Section 3. |
|           | • Only BOP formulary tuberculin should be used. |
|           | • Keep refrigerated and store in the dark. |
|           | • Skin tests should be administered as soon as possible after syringe is filled. |
|           | • 0.1 ml (5 TU) tuberculin should be injected intradermally in the volar or dorsal surface of the forearm. |
|           | • Tense white wheal (>5 mm) should appear. **If not replace at least 2 inches away.** |

| READING | • Read 48 to 72 hours after placement. |
|         | • Read palpated induration (not redness). |
|         | • Measure transversely to the long axis of the forearm. |
|         | • For no reaction, record "0 mm." |

<table>
<thead>
<tr>
<th>TST CUT-POINTS</th>
<th>≥5 mm</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>• Close contact to an active TB case.</td>
</tr>
<tr>
<td></td>
<td>• HIV co-infection (HIV risk factors and unknown status) or other immunocompromised condition.</td>
</tr>
<tr>
<td></td>
<td>• Systemic corticosteroids, treatment for organ transplantation, or other immunosuppressive therapy (equivalent to 15 mg prednisone per day for greater than 1 month).</td>
</tr>
<tr>
<td></td>
<td>• Fibrotic scarring on CXR suggestive of inactive TB.</td>
</tr>
<tr>
<td></td>
<td>• Clinical or radiographic findings suggestive of active TB.</td>
</tr>
<tr>
<td></td>
<td>• Anti-TNF alpha drugs (i.e., infliximab, etanercept, adalimumab, certolizumab and golimumab).</td>
</tr>
</tbody>
</table>

| ≥10 mm | All other inmates and correctional staff |

<table>
<thead>
<tr>
<th>TWO-STEP TESTING</th>
<th>Consider two-step testing for newly sentenced, foreign born inmates who have not had a TST in the last year.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Procedure:</strong></td>
<td>Test as usual. If negative, repeat in 1 to 3 weeks. A positive reaction on the second test is considered a boosted skin test reaction (that is a baseline TST positive) and <strong>not</strong> a TST conversion.</td>
</tr>
<tr>
<td><strong>NOTE:</strong></td>
<td>If the inmate received a TST in the last year this is considered equivalent to a two-step test and a second test is not needed.</td>
</tr>
</tbody>
</table>

| BCG | BCG vaccine is used in many countries to prevent TB disease in young children and is not a contraindication for a TST. Ignore BCG history when interpreting TST results. |

| PREGNANCY | Not a contraindication for tuberculin skin testing. |
### APPENDIX 3A. STANDARD TREATMENT FOR LATENT TB INFECTION

<table>
<thead>
<tr>
<th>ISONIAZID (INH) AND RIFAPENTINE (RPT)</th>
</tr>
</thead>
<tbody>
<tr>
<td>12-week, once-weekly INH-RPT is the standard LTBI treatment regimen in the BOP. It should be utilized to treat LTBI unless there are contraindications for its use.</td>
</tr>
</tbody>
</table>

#### MEDICAL HISTORY
- Risk factors for TB
  - See Appendix 1.
- Prior treatment for TB/LTBI
- Signs and symptoms of active TB (cough, fever, night sweats, weight loss)
- Review of CXR result
- Review of symptoms of hepatitis and liver disease
- Review of preexisting medical conditions

#### REVIEW CURRENT MEDICATIONS—especially those listed below, which have drug interactions with RPT (* = contraindicated).

<table>
<thead>
<tr>
<th>Warfarin (Coumadin) *</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antiepileptic drug therapy *</td>
</tr>
<tr>
<td>- Phenytoin</td>
</tr>
<tr>
<td>- Phenobarbital</td>
</tr>
<tr>
<td>- Carbamazepine</td>
</tr>
<tr>
<td>- Clonazepam</td>
</tr>
</tbody>
</table>

#### Calcium channel blockers, including:
- Amlodipine
- Diltiazem
- Felodipine
- Isradipine

#### Contraindications:
- Suspected/confirmed active TB
- Anticipated duration of incarceration is less than 12 weeks. (If high risk, prescribe 9-month INH.)
- Source case known to have TB organism resistant to rifampin or INH
- HIV infection on ART
- Hepatitis C treatment
- Pregnancy
- Warfarin (Coumadin) therapy
- Anti-epileptic drug therapy (phenytoin, phenobarbital, carbamazepine, clonazepam)
- Hypersensitivity INH or rifamycins (rifampin, rifabutin)

#### Dosage Guidelines: Isoniazid (INH)

<table>
<thead>
<tr>
<th>Kg</th>
<th>Pounds</th>
<th>INH Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤ 40</td>
<td>&lt; 88</td>
<td>15 mg/kg*</td>
</tr>
<tr>
<td>41–46</td>
<td>89–101</td>
<td>700 mg</td>
</tr>
<tr>
<td>47–53</td>
<td>103–116</td>
<td>800 mg</td>
</tr>
<tr>
<td>≥54</td>
<td>≥117</td>
<td>900 mg (max) (three 300mg tabs)</td>
</tr>
</tbody>
</table>

INH is formulated as 100 mg and 300 mg tablets.

* Round up to the nearest 50 mg.

#### Dosage Guidelines: Rifapentine (RPT)

<table>
<thead>
<tr>
<th>Kg</th>
<th>Pounds</th>
<th>RPT Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>25.1–32</td>
<td>55–70</td>
<td>600 mg</td>
</tr>
<tr>
<td>32.1–49.9</td>
<td>71–109</td>
<td>750 mg</td>
</tr>
<tr>
<td>≥ 50</td>
<td>≥ 110</td>
<td>900 mg (max) (six 150mg tabs)</td>
</tr>
</tbody>
</table>

Rifapentine is formulated as 150 mg tabs (keep sealed until use in blister packs).

#### Pyridoxine (Vitamin B-6).
Administer 50 mg once weekly with each dose of INH-RPT.

#### Adverse Effects:
- Possible hypersensitivity reactions occur in ~4% of patients including: fever, chills, headache, fatigue, red eyes, dizziness, urticaria, pruritus, musculoskeletal pain, and/or petechiae, and rarely hypotension.
- Hepatotoxicity
- Thrombocytopenia
- Rifapentine turns urine and tears orange.

**Alert** If patients present with fever, yellow eyes, dizziness, rash, or aches or greater than 1 day of nausea, vomiting, weakness, abdominal pain, or loss of appetite, then LTBI treatment should be withheld while the cause of symptoms is being determined.

#### Baseline and Ongoing Monitoring:
See Appendix 3c.
## APPENDIX 3B. ALTERNATIVE REGIMENS FOR TREATMENT OF LATENT TB INFECTION

### 9-MONTH ISONIAZID (INH)

<table>
<thead>
<tr>
<th>REGIMEN</th>
<th>DOSING</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>9 month regimen</td>
<td><strong>Twice-Weekly:</strong> 15 mg/kg (max: 900 mg) 9 mos: 76 doses</td>
<td>Alternative regimen if 12-week INH-RPT is contraindicated. Prescribe 9-month INH if LTBI treatment is indicated (e.g., contact to TB case), and inmate has a short length of stay. Give pyridoxine (B6) 50 mg daily per dose of INH to prevent INH-associated peripheral neuropathy (may increase pyridoxine if neuropathy occurs).</td>
</tr>
<tr>
<td></td>
<td><strong>Daily:</strong> 5 mg/kg (max: 300 mg) 9 mos: 270 doses</td>
<td></td>
</tr>
</tbody>
</table>

### SIDE EFFECTS
- Hepatic enzyme elevation
- Hepatitis
- Peripheral neuropathy
- Mild central nervous system effects
- Drug interactions resulting in increased phenytoin (Dilantin) or Disulfiram (Antabuse) levels

### DAILY RIFAMPIN (RIF)

<table>
<thead>
<tr>
<th>REGIMEN</th>
<th>DOSING</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>4 months</td>
<td><strong>Daily Only:</strong> 10 mg/kg (max: 600 mg) 4 mos: 120 doses 6 mos: 180 doses</td>
<td>Alternative regimen if INH is contraindicated or adverse reaction is suspected due to INH. Efficacy data are not as strong as for isoniazid; therefore, isoniazid is preferred. Rifampin has numerous drug interactions – see list on Appendix 3a for drug interactions with rifapentine (RPT).</td>
</tr>
<tr>
<td>6 months for HIV-seropositive</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### ADVERSE REACTIONS
- Rash
- Hepatitis
- Fever
- Thrombocytopenia
- Flu-like symptoms
- Orange-colored body fluids (urine, tears)
**APPENDIX 3C. TREATMENT OF LTBI: BASELINE AND ONGOING MONITORING**

**ALWAYS rule out TB disease with a CXR & symptom screen prior to starting LTBI treatment.**

<table>
<thead>
<tr>
<th>Test/Screen</th>
<th>12-week INH-RPT*</th>
<th>9-month INH*</th>
<th>4-month RIF*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline chest radiograph (PA) (within 6 mos., 1 mo. if HIV-infected)</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Place on Medical Hold (BEMR/SENTRY)</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
</tbody>
</table>

**BASELINE LABS**

<table>
<thead>
<tr>
<th>Test</th>
<th>12-week INH-RPT*</th>
<th>9-month INH*</th>
<th>4-month RIF*</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV (^1)t</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>HbsAg (^1) and Anti-HCV (^1)</td>
<td>X (if risk factors)</td>
<td>X (if risk factors)</td>
<td>X (if risk factors)</td>
</tr>
<tr>
<td>ALT/AST (obtain bilirubin if elevated)</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>CBC w/ platelets</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
</tbody>
</table>

**LAB MONITORING**

For inmates with the following hepatic risk factors, obtain ALT/AST after 4 wks of treatment & periodically thereafter:

- Abnormal baseline ALT/AST, HIV infection, chronic liver disease (due to alcohol/viral hepatitis/other causes), other hepatotoxic drugs prescribed, pregnancy, history of adverse reaction to LTBI.

- **Discontinue LTBI treatment if ALT or AST is greater than 3 times the upper limit of normal (if associated with symptoms) and greater than 5 times the upper limit of normal (if no symptoms).**

**BASELINE/ONGOING SCREENING FOR ADVERSE REACTIONS (recorded in BEMR Latent TB Flow Sheet)**

<table>
<thead>
<tr>
<th>Symptom</th>
<th>INH-RPT Weekly</th>
<th>INH Monthly</th>
<th>RIF Monthly</th>
</tr>
</thead>
<tbody>
<tr>
<td>Numb hands/feet</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Headache</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Seizure</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Vision decrease</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Memory loss</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Appetite loss</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Nausea/vomiting</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Yellow skin or eyes</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Fatigue</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Weight loss</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Brown urine</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Diarrhea (^2)</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Dizziness (^2)</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Fever or chills (^2)</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Rash or hives (^2)</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Sore muscles or joints (^2)</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
</tbody>
</table>

\(^1\) Only obtain HIV, hepatitis B and C serologies if they were not previously obtained in the BOP.

\(^2\) Record in the “Comments” section of the BEMR Latent TB Flow Sheet.

**Count doses to date and record in BEMR Latent TB Flow Sheet “Comments”**

<table>
<thead>
<tr>
<th>Count doses to date</th>
<th>12-week</th>
<th>76 twice-weekly</th>
<th>120 daily (180 if HIV)</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
</tbody>
</table>

**TOTAL DOSES FOR COMPLETION**

- 12 weekly
- 76 twice-weekly
- 120 daily (180 if HIV)

**Clinician Evaluation**

Inmates should be clinically evaluated by the responsible physician/mid-level provider as follows:

- treatment initiation, if signs and symptoms of adverse events and whenever treatment is interrupted.

**Managing Treatment Interruptions**

- If 50% or fewer doses have been missed within the intended treatment period, then continue therapy.
- If greater than 50% of doses have been missed within the intended treatment period, then restart therapy.

* **INH = isoniazid, RPT = rifapentine, RIF = rifampin**
APPENDIX 4. TB CASE MANAGEMENT CHECKLIST

This checklist is meant to guide BOP clinicians and Infection Prevention & Control (IP&C) Coordinators in the management of inmates with suspected TB disease (i.e., symptoms of TB disease and/or an abnormal CXR consistent with TB). The 16 steps do not necessarily need to take place in numerical order, and may occur simultaneously.

☐ 1. Conduct initial clinical assessment. (Physician/MLP)

a) Tuberculin skin test. Also consider QuantiFERON or T-Spot if TB is suspected and TST is negative.

   ALERT: TST is “false negative” in 25% of persons diagnosed with TB disease.

   ALERT: A negative TST or IGRA does not rule out TB disease.

b) Obtain chest x-ray (posterior-anterior (PA) and lateral views if TB is suspected).
   - The chest x-ray must be obtained as soon as possible if symptoms of TB disease.
   - If TB symptoms, request STAT CXR reading. If possible, the ordering clinician should also provide a “wet reading” (immediate impression). Forward reports to the Clinical Director.

   ALERT: In HIV infected patients with TB disease, the TST and/or CXR may be negative (or the CXR may have an atypical presentation)

c) Evaluate for TB signs and symptoms—cough of two or more week’s duration and systemic symptoms (e.g., night sweats, fever, chills, unexplained weight loss, fatigue, anorexia, hoarseness).

   ALERT: Inmates with TB disease may appear healthy and deny symptoms.

d) Obtain weight and compare to previous weights.

e) Obtain medical history, including:
   - TB history: History of TB exposure, prior TST or IGRA, prior TB infection or disease.
   - Risk factors for TB infection: Country of origin, history of injection drug use, incarceration, homelessness or long term care.
   - Medical conditions that increase the risk for developing TB disease, if infected:
     - HIV infection
     - TST conversion in previous 2 years
     - Fibrotic scarring on chest x-ray, consistent with old-healed TB
     - Diabetes mellitus
     - Chronic renal failure
     - Injection drug use
     - Organ transplant recipient
     - Immunosuppressant therapy (equivalent to 15 mg prednisone/day for 1 month)
     - Anti-TNF alpha therapy (e.g.,
       - infliximab (Remicade®),
       - etanercept (Enbrel®),
       - adalimumab (Humira®),
       - certolizumab (Cimzia®)
       - golimumab (Simponi®)
     - Silicosis
     - Leukemia/lymphomas
     - Carcinomas of head, neck, lung
     - Underweight (>10% under ideal weight)
     - History of gastrectomy/jejuno-ileal bypass
   - Risk factors for multiple drug resistant (MDR) TB: Prior TB treatment, immigration from or extended travel to a country with a high incidence of MDR-TB.

f) Physician or mid-level provider shall perform physical examination.

g) Baseline laboratory tests: HIV, fasting CMP (comprehensive metabolic panel), uric acid, CBC with platelets. Obtain HBsAg and anti-HCV if risk factors are present for viral hepatitis.
2. Notify health services and correctional leadership.

Immediately notify institution leadership about suspected TB case. If transport to a hospital for isolation is indicated, then advise regarding the need for N-95 fit-tested officers for transport.

3. Initiate respiratory protection and isolation.

- Inmates with suspected TB should be placed in an airborne infection isolation room (AIIR) immediately (either in the facility or transported to a community hospital).
  - While awaiting isolation, the inmate must wear a surgical mask. Replace mask if it becomes wet or torn.
  - Place inmate in low traffic area until he/she can be isolated.
  - Fit-tested staff must wear an N-95 respirator mask when in contact with the patient.
- Determine where inmate will be isolated.
  - If facility has an AIIR:
    - Was room validated in last year? (If not, send inmate to hospital.)
    - Monitor AIIR daily while in use (tissue test daily for negative pressure).
    - Assure that inmate is seen daily while isolated, with clinical encounter documented.
  - If facility does not have an AIIR, then transport inmate to a local hospital for isolation and diagnostic evaluation:
    - Inmate wears surgical mask. Staff wear fit-tested N-95 respirator mask.
    - Contact hospital Emergency Department and Infection Prevention staff to notify them of case & establish point of contact.
    - Send hospital Appendix 7, Criteria for Discontinuation of Airborne Infection Isolation and Return of an Inmates with Suspected TB to General Population.


Report suspected TB cases within one working day (utilizing the BP-A0665 form) to:
- Regional MAST QM & Central Office IP&C (email addresses on Sallyport/HSD/Infectious Diseases)
- Local Health Department (The BP-A0665 form can substitute for health department report form.)
- Scan form and updates into BEMR Documents Manager ("Flowsheet" labeled “TB Report”).

5. Participate in TB case management teleconference.

Schedule conference call with Regional QM Coordinator to review plan of care (especially facilities that rarely diagnose TB). Consider including facility health services leadership and executive staff.

6. Collect sputum specimens.

- Obtain three sputum specimens:
  - At least 8 hours apart, including at least one early AM specimen.
  - If necessary, induce sputum (see Appendix 5, Sputum Collection Procedures).
  - If possible, use your local/state health department lab for specimens.
  - Sputum request should include: AFB smears, cultures, and nucleic acid amplification (NAAT/PCR/DNA) test.
  - A bronchoscopy specimen may be substituted for one sputum specimen. If bronchoscopy is done, obtain sputum after bronchoscopy.
- Obtain sputum smears & NAAT/PCR results (~24 hours). See Table 1 for NAAT interpretation.

  **ALERT:** Negative AFB smears from sputum or bronchoscopy DO NOT rule out active TB!!
### 7. Place on Medical Hold.

Place on Medical Hold in both BEMR and SENTRY.

### 8. Conduct vision tests prior to TB treatment initiation.

Vision tests (required for ethambutol): Snellen (visual acuity) and Ishihara (color vision plates)

### 9. Initiate TB Treatment.

- 4-drug daily Rifampin/Isoniazid/Pyrazinamide/Ethambutol (RIPE) plus pyridoxine (vitamin B6)
  - 50 mg with each dose. See Appendix 6a and Appendix 6b for prescribing information.
  - *If a different regimen is prescribed, contact Regional/Central Office to discuss.*
  - Check with pharmacist to assure correct weight-based doses for pyrazinamide/ethambutol.
  - *All medication doses must be directly observed. Place on pill line.*
  - *Completion of treatment is based upon number of COUNTED DOSES ingested, NOT on the amount of time elapsed.*

### 10. Initiate Discharge Planning.

Determine Projected Release Date (PRD). Immediately begin release planning if inmate’s PRD is before anticipated treatment completion (see Section 9, Discharge Planning).

- *The updated BP-A0665 form is used as the referral form for inmates who are releasing before the TB diagnostic work-up or treatment is complete.*

### 11. Initiate contact investigation, if indicated.

See Section 7 and Appendix 8 to determine if contact investigation is indicated. Consult with Regional Quality Management/Central Office IP&C staff.

### 12. Assess if isolation can be discontinued.

Regularly determine if isolation can be discontinued (see criteria in Appendix 7). If isolation extends greater than 14 days, hold weekly case conferences to assure that isolation is discontinued as soon as possible.

### 13. Clinician Evaluation

At a minimum, patients on treatment for active TB disease should be evaluated by a physician or qualified mid-level provider (with physician review) at:

- initiation of treatment
- at ~2 months of treatment
- if signs and symptoms of adverse reactions or lack of clinical response
- whenever treatment is interrupted
- at treatment completion
- monthly throughout treatment if drug resistant TB, drug intolerance or HIV co-infection

Inmates with baseline elevations of liver transaminases or other complicating medical conditions should be followed closely.
14. **Monitor for treatment response and adverse reactions.**

Monitor weekly for the first few weeks, and then at least monthly. Utilize the clinical encounter for Active TB Monitoring in BEMR to record results of monitoring.

- **TB symptom review:** Coughing, coughing up blood, fever, night sweats, chest pain
- **Adverse Reactions:** Nausea, abdominal pain, vomiting, dark urine, decreased appetite, fatigue, headache, joint pain, memory loss, nausea, numbness in hands/feet, rash/itching, seizure, vision decrease, yellow skin or eyes.
- **Weight:** Assess for weight gain if weight loss occurred initially.
- **Bacteriology:** Obtain sputum specimens in AIIR or outside.
  - If initially AFB sputum smear positive, then obtain 3 sputum specimens weekly until 3 consecutive negative AFB smears.
  - Obtain 3 sputum specimens monthly at least 8 hours apart, including at least one early morning sputum, until 3 consecutive negative cultures (culture conversion).
    - See Appendix 6c if culture positive after 2 months of RIPE.
  - Obtain all smear, NAAT, culture reports. Record results on the BP-A0665 form with the lab accession numbers.
  - For culture-positive patients, obtain drug susceptibility reports.
- **ALT/AST:** Perform monthly if any of the following risk factors:
  - abnormal baseline ALT/AST; HIV; chronic liver disease (due to alcohol/viral hepatitis/other causes); other hepatotoxic drugs prescribed; pregnancy; history of adverse reaction to TB medications
- **Vision (only while on Ethambutol):** Monthly Snellen and Ishihara. For patients on ethambutol for more than 3 months, vision should be assessed every 3 months by an optometrist.
- **Chest Radiograph (CXR):**
  - Ongoing CXR monitoring is done only if clinically indicated.
  - If AFB cultures are negative at 6-8 weeks, then obtain CXR after 8 weeks of treatment (56 doses). Request CXR comparison with prior CXRs.
    - See Section 6, *Culture-Negative TB.*
- **Medication Monitoring:**
  - At least monthly, count and record total doses to-date.
    - Do not switch to two drugs (INH/rifampin) until drug susceptibility is known and pyrazinamide has been given for a total of 2 months (56 doses). *Exception: culture-negative TB*
- **Update BP-A0665 TB Case/Suspect Report & Referral Form.**
  As additional information becomes available (e.g., new lab reports, susceptibility reports, dose counts at completion of treatment phases), update form and scan updates into BEMR.

15. **Complete final steps after treatment completion.**

- Discontinue Medical Hold.
- Obtain end-of-treatment CXR (to serve as a baseline CXR for future comparisons).
- Perform final dose count (record in clinical encounter and BP-A0665 form).

16. **Complete and file final updated BP-A0665 form.**

Update form with all available information and file in Documents Manager. If the inmate has left the facility make arrangements for the form to be scanned into the BEMR.

*This final BP A0665 form update is a critically important record tracing the history of the patient's diagnostic work-up and treatment for TB, to be available for future reference.*
APPENDIX 5. SPUTUM COLLECTION / INDUCTION PROCEDURES

INFECTION CONTROL

Sputum expectoration or induction for acid-fast bacilli (AFB) smear and culture should be performed in an airborne infection isolation room (AIIR). Facilities that lack AIIRs should have a local protocol for referral and safe transport of tuberculosis (TB) suspects to local hospital until the criteria for discontinuing isolation is met (see Appendix 7).

Inmates who are undergoing TB treatment, and who have met the criteria for discontinuation of isolation, should have three sputa obtained monthly either in an AIIR or, if locally feasible, outdoors.

EXPECTORATED SPUTUM COLLECTION PROCEDURE

• Collection of early morning specimens is preferred because of the overnight accumulation of secretions; however, you may collect specimens at any time for patients who have a deep cough that is readily productive. Taking a hot shower immediately prior to sputum collection can sometimes aid in sputum production.

• Sputum should be collected under direct observation. If the inmate is able to perform on their own, staff should exit the AIIR and observe from view window (if available); otherwise, staff should keep the respirator on and supervise the inmate. Keep the AIIR door closed.

• Equipment needed:
  ► Wide-mouthed sterile container with a screw-top lid or a container provided by the lab
  ► Lab slip
  ► Cup of water, tissues
  ► For staff: respirator (N-95 or higher) and gloves

• Before the procedure, have the inmate remove any dentures and rinse mouth well with water (or drink water) to remove food particles and bacteria.

• Instruct the patient to breathe deeply and cough from deep down in the lungs. Instruct them that saliva and upper respiratory secretions are not sputum and are not acceptable specimens.

• Assess the adequacy of the specimen. Specimen should consist of 3–5 ml of thick, mucoid sputum, and not saliva or nasal secretions (i.e., a thin, clear sample is not acceptable).

• Patients who have difficulty producing sputum should undergo sputum induction (see below).

SPUTUM INDUCTION PROCEDURE

Sputum induction is a procedure for obtaining sputum from patients who have difficulty producing it spontaneously. In this procedure, patients inhale a mist of nebulized, sterile normal saline that irritates their airways, causing them to cough and produce respiratory secretions.

• Sputum induction must be ordered by a physician and supervised by a trained staff member.

• Sputum induction must be performed in a functioning AIIR or sputum induction booth.

• Additional equipment for obtaining an induced sputum include:
  ► Nebulizer and table to support nebulizer
  ► Disposable tubing with cup and lid
  ► Sterile normal saline

(Appendix 5, Sputum Collection/Induction Procedure (page 1 of 2)
• Prepare the equipment:
  ► Place sterile normal saline in the nebulizer chamber to the level marked on the chamber.
  ► Place a small amount of normal saline in the cup portion of the disposable nebulizer tubing.
  ► Insert the cup into the nebulizer.
  ► Test to make sure the nebulizer is functional by turning it on and checking to see whether it produces a mist.

• Prepare the patient:
  ► Explain the purpose of the procedure.
  ► Orient the patient to the nebulizer and demonstrate how it works.
  ► Provide water in a disposable cup and explain that drinking it will help with the procedure.

• Provide the patient with these instructions:
  ► Inhale the aerosol by taking 3 or 4 deep, slow breaths through the mouth without placing his/her mouth on the tubing.
  ► Cough vigorously (if coughing does not start spontaneously).
  ► Cover their mouth with a tissue when coughing unless expectorating into the sputum container.
  ► Continue trying to cough and to expectorate after inhaling the mist.
  ► Expectorate all sputum into the sputum container.
  ► Cover the sputum container tightly after collecting about 1 tablespoon of sputum.

Infection Control Practices
• Wear respirator when in the room with the patient. Wear gloves when handling specimens.
• Always wash hands with soap and water before procedures and after handling specimen containers.

Sample Labeling, Handling, and Transport
• Labeling:
  ► In the presence of the patient, label the side of the specimen collection container to include: name of the inmate, registration number, date of birth, and date and time of collection.
  ► Lab slip should include inmate identifiers, facility name and address, and the reason for exam (i.e., active TB suspect, TB chemotherapy follow-up).
  ► Aerosol induced sputum samples should be clearly labeled as “induced sputum.”
  ► On the lab slip, also record the visual appearance of the sample, including the color (e.g., white, green, red, or brown), the consistency (e.g., thick and mucoid), and the amount (ml).
• Place the sample in a biohazard bag. Refrigerate the sample until transported.
• Preferably on the day of collection, transport or mail the sample to the laboratory, by airmail or overnight courier.


(Appendix 5, Sputum Collection/Induction Procedure (page 2 of 2)}
## APPENDIX 6A. STANDARD TUBERCULOSIS TREATMENT REGIMEN – 6 MONTHS

<table>
<thead>
<tr>
<th>INITIAL PHASE – 2 MONTHS*</th>
<th>CONTINUATION PHASE – 4 MONTHS*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Drugs:</strong> RIF, INH, PZA, EMB (RIPE)</td>
<td><strong>Drugs:</strong> RIF, INH</td>
</tr>
<tr>
<td>8 weeks daily therapy</td>
<td>18 weeks daily therapy</td>
</tr>
<tr>
<td>Total: 56 <em>counted</em> doses</td>
<td>Total: 126 <em>counted</em> doses</td>
</tr>
</tbody>
</table>

**Pyridoxine** (Vitamin B6) 50 mg should be administered with each dose of TB medication to prevent INH-associated peripheral neuropathy.

- Medication doses are weight-based.
- All doses are administered once daily (no divided doses).

**KEY:** RIF = rifampin, INH = isoniazid, PZA = pyrazinamide, EMB = ethambutol

### CLINICAL NOTES:
- Do not wait for confirmation of TB diagnosis to start treatment.
- Report suspected or confirmed cases to Regional and Central office and local health department using BP-A0665 form.
- Ingestion of all drug doses should be directly observed by a healthcare worker.
- For culture positive cases, do not switch to two drugs (RIF/INH only) until susceptibility to both INH and RIF has been demonstrated.
- See [Appendix 4](#) for recommended baseline and monthly medical monitoring.
- Determine the Projected Release Date (in BEMR under File/Inmate Detail), and immediately begin discharge planning if release is anticipated during treatment or if the Projected Release Date is “Unknown.”
  - See [Section 9, Discharge Planning](#).
- Place inmates on Medical Hold in SENTRY and BEMR for the duration of treatment.
- **CULTURE NEGATIVE TB:** Inmates with a positive TST or IGRA and CXR evidence of active TB (with or without symptoms) may be started on RIPE treatment—if initial AFB smears are negative. If AFB cultures are negative (after 6-8 weeks), repeat CXR in 8 weeks. If CXR improves, treatment is continued for 8 additional weeks with INH/RIF (16 additional weeks if HIV-positive or cavitary CXR). If CXR does not improve the 8 weeks of RIPE, this is considered complete treatment for latent TB infection and the inmate should be coded as such.
  - See [Section 6, Culture-Negative TB](#).

### EXCEPTIONS:
Refer to [Appendix 6c](#) for the following exceptions to the standard regimen:
- HIV infection
- Pregnancy
- Drug resistance
- Failure to convert sputum cultures in 2 months
- Bone/joint TB
- TB meningitis
### APPENDIX 6B. FIRST-LINE TUBERCULOSIS DRUG DOSES

<table>
<thead>
<tr>
<th>DRUG</th>
<th>STANDARD DAILY THERAPY (maximum dose)</th>
<th>FOR RENAL INSUFFICIENCY (creatinine clearance &lt;30 ml/min.)¹</th>
<th>DAILY (maximum dose)</th>
<th>DIALYSIS PATIENTS THREE TIMES WEEKLY (maximum dose)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Isoniazid (INH)</td>
<td>5 mg/kg (300 mg max)</td>
<td>5 mg/kg (300 mg max)</td>
<td>15 mg/kg (900 mg)</td>
<td></td>
</tr>
<tr>
<td>Rifampin (RIF)</td>
<td>10 mg/kg (600 mg max)</td>
<td>10 mg/kg (600 mg max)</td>
<td>10 mg/kg (600 mg)</td>
<td></td>
</tr>
<tr>
<td>Rifabutin (RBT)</td>
<td>5 mg/kg (300 mg max)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pyrazinamide (PZA)</td>
<td>15–30 mg/kg (2000 mg max)</td>
<td>Do not use</td>
<td>25–35 mg/kg (3000 mg)</td>
<td></td>
</tr>
<tr>
<td>Ethambutol (EMB)¹</td>
<td>15–25 mg/kg (1600mg max)</td>
<td>Do not use</td>
<td>15–25 mg/kg (2400 mg)</td>
<td></td>
</tr>
</tbody>
</table>

¹ Start with EMB 15 mg/kg to reduce the risk of ocular toxicity. The use of 25 mg/kg should be reserved for patients requiring retreatment or drug resistant TB.

² For patients on hemodialysis, administer medication 3 times weekly after dialysis, on the day of dialysis, using renal insufficiency dosing in the table above.

#### WEIGHT ADJUSTED DOSAGES (MG/KG)

<table>
<thead>
<tr>
<th>lb</th>
<th>kg</th>
<th>5 mg/kg</th>
<th>10 mg/kg</th>
<th>15 mg/kg</th>
<th>20 mg/kg</th>
<th>25 mg/kg</th>
<th>30 mg/kg</th>
<th>40 mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>77</td>
<td>35</td>
<td>175</td>
<td>350</td>
<td>525</td>
<td>700</td>
<td>875</td>
<td>1050</td>
<td>1400</td>
</tr>
<tr>
<td>88</td>
<td>40</td>
<td>200</td>
<td>400</td>
<td>600</td>
<td>800</td>
<td>1000</td>
<td>1200</td>
<td>1600</td>
</tr>
<tr>
<td>99</td>
<td>45</td>
<td>225</td>
<td>450</td>
<td>675</td>
<td>900</td>
<td>1125</td>
<td>1350</td>
<td>1800</td>
</tr>
<tr>
<td>110</td>
<td>50</td>
<td>250</td>
<td>500</td>
<td>750</td>
<td>1000</td>
<td>1250</td>
<td>1500</td>
<td>2000</td>
</tr>
<tr>
<td>121</td>
<td>55</td>
<td>275</td>
<td>550</td>
<td>825</td>
<td>1100</td>
<td>1375</td>
<td>1650</td>
<td>2200</td>
</tr>
<tr>
<td>132</td>
<td>60</td>
<td>300</td>
<td>600</td>
<td>900</td>
<td>1200</td>
<td>1500</td>
<td>1800</td>
<td>2400</td>
</tr>
<tr>
<td>143</td>
<td>65</td>
<td>325</td>
<td>650</td>
<td>975</td>
<td>1300</td>
<td>1625</td>
<td>1950</td>
<td>2600</td>
</tr>
<tr>
<td>154</td>
<td>70</td>
<td>350</td>
<td>700</td>
<td>1050</td>
<td>1400</td>
<td>1750</td>
<td>2100</td>
<td>2800</td>
</tr>
<tr>
<td>165</td>
<td>75</td>
<td>375</td>
<td>750</td>
<td>1125</td>
<td>1500</td>
<td>1875</td>
<td>2250</td>
<td>3000</td>
</tr>
<tr>
<td>176</td>
<td>80</td>
<td>400</td>
<td>800</td>
<td>1200</td>
<td>1600</td>
<td>2000</td>
<td>2400</td>
<td>3200</td>
</tr>
<tr>
<td>187</td>
<td>85</td>
<td>425</td>
<td>850</td>
<td>1275</td>
<td>1700</td>
<td>2125</td>
<td>2550</td>
<td>3400</td>
</tr>
<tr>
<td>198</td>
<td>90</td>
<td>450</td>
<td>900</td>
<td>1350</td>
<td>1800</td>
<td>2250</td>
<td>2700</td>
<td>3600</td>
</tr>
<tr>
<td>209</td>
<td>95</td>
<td>475</td>
<td>950</td>
<td>1425</td>
<td>1900</td>
<td>2375</td>
<td>2850</td>
<td>3800</td>
</tr>
<tr>
<td>220</td>
<td>100</td>
<td>500</td>
<td>1000</td>
<td>1500</td>
<td>2000</td>
<td>2500</td>
<td>3000</td>
<td>4000</td>
</tr>
<tr>
<td>231</td>
<td>105</td>
<td>525</td>
<td>1050</td>
<td>1575</td>
<td>2100</td>
<td>2625</td>
<td>3150</td>
<td>4200</td>
</tr>
<tr>
<td>242</td>
<td>110</td>
<td>550</td>
<td>1100</td>
<td>1650</td>
<td>2200</td>
<td>2750</td>
<td>3300</td>
<td>4400</td>
</tr>
</tbody>
</table>
## APPENDIX 6C. TUBERCULOSIS TREATMENT REGIMENS IN SPECIAL SITUATIONS

<table>
<thead>
<tr>
<th>SITUATION</th>
<th>MONTHS OF RX</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cavitary CXR &amp; Culture (+) after 2 mos.</td>
<td>9</td>
<td>If initial CXR shows cavitation and sputa remain culture positive after 2 months of TB treatment, the continuation phase (INH and RIF) should be extended an additional 3 months (lasting 7 months instead of 4 months), for a total of 9 months of treatment.</td>
</tr>
<tr>
<td>Culture-negative TB</td>
<td>4</td>
<td>For persons with suspected pulmonary TB who have negative cultures, but clinical or radiographic improvement after 8 weeks of TB treatment, the continuation phase (INH and RIF) is 8 additional weeks (total 16 weeks) of treatment. Exception: If HIV seropositive or cavitation on CXR, then continuation phase is 18 additional weeks.</td>
</tr>
<tr>
<td>Bone/Joint TB</td>
<td>9</td>
<td>Extend standard therapy to a total of 9 months.</td>
</tr>
<tr>
<td>CNS TB</td>
<td>9 to 12</td>
<td>For TB meningitis, extend standard therapy for a total of 9 to 12 months. Adjunctive dexamethasone use is often recommended. Consult a TB expert.</td>
</tr>
<tr>
<td>HIV Co-Infection</td>
<td>usually 6</td>
<td>Treatment of HIV co-infected TB patients should be provided in consultation with an HIV/TB expert. Refer to HIV Co-Infection, under Section 6, Treatment of Tuberculosis Disease. Inmates with HIV infection should have treatment administered daily. Inmates with CD4+ T-cell counts below 100/mm³ should never be prescribed intermittent therapy. Patients on protease inhibitors and non-nucleoside inhibitors may need medication adjustments because of drug interactions with rifampin. HIV co-infected TB patients are at risk for a paradoxical reaction known as immune reconstitution inflammatory syndrome (IRIS) which presents as worsening of TB symptoms after treatment is started. Consult an HIV/TB expert. Consult CDC HIV/TB Guidelines <a href="http://www.cdc.gov/tb/publications/guidelines/TB_HIV_Drugs/default.htm">http://www.cdc.gov/tb/publications/guidelines/TB_HIV_Drugs/default.htm</a> (Tables 1, 2a, and 3).</td>
</tr>
<tr>
<td>Pregnancy</td>
<td>9</td>
<td>Treat without delay. Start with INH, RIF, and EMB (not PZA). Discontinue EMB once INH and RIF susceptibility has been demonstrated. Continue INH and RIF. Give equivalent of pyridoxine 50 mg/day (unless already taking the equivalent in a prenatal vitamin). Contraindicated: Streptomycin, Amikacin and Fluoroquinolones.</td>
</tr>
<tr>
<td>Renal Disease</td>
<td>6</td>
<td>If creatinine clearance &lt;30 ml/min. or on renal dialysis, alter dosing. If on hemodialysis, give 3 times weekly after dialysis, on the same day as dialysis. (For dosing see Appendix 6b).</td>
</tr>
</tbody>
</table>

### TREATMENT REGIMENS FOR DRUG RESISTANCE OR INTOLERANCE

<table>
<thead>
<tr>
<th>AGENT</th>
<th>MONTHS OF RX</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>INH</td>
<td>6</td>
<td>Once resistance to INH is known or INH intolerance identified, discontinue INH and continue RIF, PZA, and EMB for the duration of therapy. Note: If low level INH resistance is detected some clinicians will continue INH.</td>
</tr>
<tr>
<td>RIF</td>
<td>9 to 12</td>
<td>For rifampin resistance or intolerance, treat for 12 months with INH, PZA, EMB, and a fluoroquinolone. An injectable agent (e.g., streptomycin) for the first 2 months should be considered for more extensive disease or if a shorter duration of therapy (9 months) is desired.</td>
</tr>
<tr>
<td>PZA</td>
<td>9</td>
<td>For PZA resistance or intolerance, treat for 9 months with INH and RIF.</td>
</tr>
<tr>
<td>INH/RIF</td>
<td>18 to 24</td>
<td>Multiple drug resistant (MDR-TB). Must be closely managed in consultation with a TB expert, utilizing multiple drugs to which the organism is sensitive.</td>
</tr>
</tbody>
</table>
APPENDIX 7. CRITERIA FOR DISCONTINUATION OF AIRBORNE INFECTION ISOLATION AND RETURN OF AN INMATE WITH SUSPECTED TB TO GENERAL POPULATION

The following criteria must be met before a BOP inmate who is diagnosed with suspected or confirmed TB can be returned to the general inmate population. This criteria applies to inmates hospitalized in a community hospital or being worked up for TB in a facility airborne infection isolation room (AIIR).

**DIAGNOSTIC WORK-UP**

The TB diagnostic workup should include the following components:

- Three sputum specimens for acid fast bacilli (AFB)
  - Collected at least 8 hours apart, including at least one early morning specimen.
  - Test for AFB smear and culture
  - Request a nucleic acid amplification test (NAAT/PCR) for at least one test.
    - If a bronchoscopy is performed, then bronch specimen can serve as one of the specimens.
  - Obtain a sputum after bronchoscopy (significantly higher yield for AFB)
- HIV test

**Important Clinical Notes**

- Negative AFB smears from sputum & bronchoscopy DO NOT rule out active TB.
- In general, avoid use of fluoroquinolones (e.g., ciprofloxacin, levofloxacin) if TB is in differential diagnosis. They are highly effective agents against TB and can confuse the diagnostic work-up.

**CRITERIA FOR DISCONTINUATION OF ISOLATION / RETURN TO GENERAL INMATE POPULATION**

Before an inmate can be returned to general population they must have either:

1. An alternative diagnosis that clearly explains the pulmonary abnormality  **OR**
2. Meet one of the criteria for discontinuation of isolation listed below.

**AFB AND CXR RESULTS**

<table>
<thead>
<tr>
<th>AFB and CXR Results</th>
<th>NAAT</th>
<th>Criteria for Discontinuation of Isolation</th>
</tr>
</thead>
<tbody>
<tr>
<td>If AFB smear neg x 3 &amp; non-cavitary CXR</td>
<td>and  - Neg  - Pos  - Not done</td>
<td>then  1. &gt; 5 days of RIPE treatment  <strong>and</strong>  2. If symptomatic, then definite clinical improvement$^b$</td>
</tr>
<tr>
<td>If AFB smear neg x 3 &amp; cavitary CXR</td>
<td>and  - Neg  - Pos  - Not done</td>
<td>then  1. 14 days of RIPE$^a$ treatment  <strong>and</strong>  2. If symptomatic, then definite clinical improvement$^b$</td>
</tr>
<tr>
<td>If AFB smear positive, regardless of CXR presentation</td>
<td>and  - Neg</td>
<td>then  Obtain expert consultation through Regional/Central Office Infection Prevention &amp; Control</td>
</tr>
<tr>
<td>If AFB smear positive, regardless of CXR presentation</td>
<td>and  - Pos  - Not done</td>
<td>then  1. At least 14 days of RIPE$^a$ treatment  <strong>and</strong>  2. If symptomatic, then definite clinical improvement$^b$ <strong>and</strong>  3. Subsequent negative AFB smears</td>
</tr>
</tbody>
</table>

**CRITERIA FOR DISCONTINUATION OF ISOLATION FOR MDR-TB**

1. Three consecutively negative sputum smears and no subsequent positive smear;  **and**
2. At least 14 daily directly observed doses of treatment for MDR-TB taken and tolerated;  **and**
3. Evidence of clinical improvement$^c$;  **and**
4. At least 2 consecutive negative sputum cultures without a subsequent positive culture.

$^a$ RIPE = rifampin, isoniazid, pyrazinamide, ethambutol

$^b$ Clinical Improvement, i.e., resolution or significant reduction in cough if inmate initially presents with a cough; improved sense of well-being; weight gain if prior weight loss

$^c$ MDR-TB = multiple drug resistant TB (TB resistant to at least INH and rifampin)

APPENDIX 8. TUBERCULOSIS CONTACT INVESTIGATION – CHECKLIST

After identification of a TB case or suspected case, the inmate should be immediately isolated, medically evaluated, and (if appropriate) treated.

- The case should be immediately reported to the local or state health department.
- The contact investigation steps outlined below may overlap in time.
- Close contacts should be evaluated promptly.

<table>
<thead>
<tr>
<th>✓</th>
<th>Date</th>
<th>Task</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td></td>
<td>Notify correctional management officials.</td>
</tr>
<tr>
<td>2.</td>
<td>Perform clinical assessment of the TB case (including retrospective chart review):</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Previous exposure to TB. TB risk factors (Appendix 1)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>History of TB symptoms (cough, fever, night sweats, etc.). Weight history</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chest radiographs</td>
<td></td>
</tr>
<tr>
<td></td>
<td>TST/IGRA</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bacteriology (AFB smear/culture/susceptibilities), nucleic acid amplification tests</td>
<td></td>
</tr>
<tr>
<td></td>
<td>HIV status</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Other medical conditions</td>
<td></td>
</tr>
<tr>
<td>3.</td>
<td>Interview case. For AFB smear-positive or cavitary cases, interview within 1 day; for all others, interview within 3 days. Re-interview in 7–14 days. Interview for: TB symptom history/onset of symptoms and close contacts in correctional facility and community (if relevant). See Appendix 9, TB Contact Investigation Interview.</td>
<td></td>
</tr>
<tr>
<td>4.</td>
<td>Determine the infectious period to determine how far back in time to go for investigation of TB contacts.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Generally: 12 weeks before symptom onset or first positive findings consistent with TB disease, whichever is longer.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Exception: If no TB symptoms, and AFB smear negative and non-cavitary, then 4 weeks prior to suspected TB.</td>
<td></td>
</tr>
<tr>
<td>5.</td>
<td>Convene contact investigation team (include institution &amp; regional health services &amp; custody staff):</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Identify team leader; identify roles and responsibilities of team members.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Develop plan for managing contact investigation data.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Develop investigational priorities.</td>
<td></td>
</tr>
<tr>
<td>6.</td>
<td>Update correctional management officials (including the Warden, Regional staff, and Central Office HSD staff) regarding contact investigation strategy.</td>
<td></td>
</tr>
<tr>
<td>7.</td>
<td>Obtain index case traffic history (housing/work/school locations during infectious period). SENTRY pp37 (Housing = QTR, Education = EDU, Work = WRK).</td>
<td></td>
</tr>
<tr>
<td>8.</td>
<td>Tour the exposure sites (where case frequented during infectious period) with the facility HVAC (heating/ventilation/air conditioning) personnel and assess:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Number of inmates housed together</td>
<td></td>
</tr>
<tr>
<td></td>
<td>General size of airspace</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Housing arrangements (cells/dorms)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Availability of data on inmates housed at same time</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ventilation: HVAC system (Recirculated air? Where does air move?)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pattern of daily inmate movement (cafeteria, general areas)</td>
<td></td>
</tr>
</tbody>
</table>

Appendix 8, TB Contact Investigation – Checklist (page 1 of 2)
<table>
<thead>
<tr>
<th>Date</th>
<th>Task</th>
</tr>
</thead>
</table>
|    | 9. **Prioritize contacts.**  
  - Contacts who are HIV-infected, on anti-TNF alpha treatment or immunosuppression for organ transplant are the highest priority contacts regardless of duration of exposure.  
  - Otherwise prioritize contacts based upon duration and/or intensity of exposure.  
  - Immediately refer to the health department the names of community contacts who are young children or who are HIV infected. |
|    | 10. **Develop contact lists.**  
  Obtain rosters of highest priority employee and inmate contacts and research their current location. Generate lists of exposed contacts grouped by their current location (currently incarcerated, transferred, and released).  
  - **Note:** Central Office Infection Prevention & Control can obtain lists of historic contacts upon request. See Sallyport/HSD/Infectious Diseases for sample spreadsheets to manage data. |
|    | 11. **Conduct a medical record review of each high priority contact,** to collect:  
  - Prior TST and CXR results  
  - History of treatment for latent TB infection or TB treatment  
  - HIV status  
  - Other high risk medical conditions |
|    | 12. **Initiate medical evaluation of contacts (employees and inmates).**  
  HIV-infected contacts should be evaluated as soon as possible.  
  - **ALL contacts:** Interview for TB symptoms and encourage HIV testing if status unknown. If TB symptoms, perform CXR and medical evaluation. Isolate in an AIIR if TB is suspected.  
  - **Prior TST positives** (HIV seronegative or unknown):  
    - Offer HIV counseling and testing and assess for symptoms  
    - No further follow-up is needed unless contact is symptomatic.  
  - **HIV-infected/anti TNF or organ transplant on immunosuppression therapy** (regardless of prior TST result):  
    - Do symptom review, TST (if prior TST negative), and chest radiograph.  
    - Initiate complete course of treatment for LTBI after active TB ruled out (regardless of prior treatment for LTBI or active TB).  
  - **Baseline TST negatives** (HIV seronegative or unknown):  
    - Do symptom review and TST.  
  - **Obtain CXR** if TST is positive. |
|    | 13. **Make referrals for contact evaluation for inmates who are transferred or released** in conjunction with Regional/Central Office. |
|    | 14. **Determine the infection rates by exposure sites.**  
  - Infection rate = total # skin tested, divided by # whose TST has converted from neg to pos.  
  - Calculate rates separately for U.S. born and foreign born inmates.  
  - Decide whether or not to expand investigation beyond highest priority contacts. |
|    | 15. **Conduct follow-up tuberculin skin testing.** Perform at 8 or more weeks **after exposure ended.**  
  - Perform record search in Sentry to determine current location of inmates.  
  - Conduct testing of employees and inmate contacts who remain incarcerated.  
  - Refer released/transferred inmates for follow-up TST. |
|    | 16. **Determine infection rate** and need to expand investigation (see Step 14 above). |
|    | 17. **Write a summary report,** submit through Warden to Regional and Central Offices. |

---

*Appendix 8, TB Contact Investigation – Checklist (page 2 of 2)*
# APPENDIX 9. TB CONTACT INVESTIGATION INTERVIEW

**Purpose:** The goal of interviewing the index case in a contact investigation is to gain the information needed for:

1. establishing the infectious period; and
2. identifying potential contacts.

**Overview:**

- It is critically important that time be spent establishing trust with the inmate before conducting the interview, and making sure that the inmate understands the purpose of the contact investigation. Use an interpreter if needed.
- The following questions should be used to guide the contact investigation interview. Depending on the inmate's responses, additional questions may be asked as follow-up on their answers.
- The inmate should be re-interviewed in 1–2 weeks to gain additional information and validate the answers.
- **Do Not** file interview documentation in the inmate's medical record.

<table>
<thead>
<tr>
<th>TB Patient Name:</th>
<th>Registration #:</th>
<th>Facility Intake Date:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interviewer Name:</td>
<td>Interview Date:</td>
<td></td>
</tr>
</tbody>
</table>

## 1. Review the TB diagnosis with the inmate:

- Assess inmate's knowledge of the condition.
- Describe TB, how it is diagnosed and treated, and the treatment plan.
- Describe how TB is transmitted (airborne).
- Discuss the need to identify potentially exposed contacts.

## 2. Ask about the inmate’s TB history:

### a. Have you known anyone with a diagnosis of TB?  □ YES □ NO. If YES, where and when?

### b. Have you ever had a positive TB skin test?  □ YES □ NO. If YES, where and when?

### c. Have you ever been diagnosed with or treated for TB?  □ YES □ NO. If YES, where and when?

## 3. Ask about the inmate’s other medical history:

What other medical conditions do you have?

## 4. Ask about the inmate’s history of TB symptoms:

<table>
<thead>
<tr>
<th>X</th>
<th>NO</th>
<th>Have you had any of the following symptoms?</th>
<th>If X, how long have you had them?</th>
<th>When did they start?</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Cough?</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Coughing up blood?</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Fever?</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chills?</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Night sweats?</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Unexplained weight loss?</td>
<td>__ pounds in ___ weeks</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chest pain?</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hoarseness?</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Likely date of symptom onset:** __/__/___

---

TB Contact Investigation – Interview Questions (page 1 of 3)
5. **Ask about the inmate’s TB risk factors:**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th>Please answer the following questions:</th>
<th>When? Where?</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>NO</td>
<td>Were you born outside the U.S.?</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Have you traveled outside the U.S.?</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Have you ever been homeless?</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Have you ever used drugs? Which ones?</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>How much alcohol do you drink?</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Before this incarceration, were you ever incarcerated?</td>
<td></td>
</tr>
</tbody>
</table>

6. **If symptoms began prior to incarceration, ask:**

   a. Where were you living?

   b. Who were you living with?

7. **Ask: Since __/__/___ (3 months before symptom onset) …**

<table>
<thead>
<tr>
<th></th>
<th>NO</th>
<th>Have you been in the same room with:</th>
<th>Who? Where?</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Any infants or young children?</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Anyone known to be HIV-infected?</td>
<td></td>
</tr>
</tbody>
</table>

8. **Please describe your previous day-to-day activities at this facility:**

<table>
<thead>
<tr>
<th>Time of Day</th>
<th>Daily Activities</th>
</tr>
</thead>
<tbody>
<tr>
<td>Morning</td>
<td></td>
</tr>
<tr>
<td>Mid-Day</td>
<td></td>
</tr>
<tr>
<td>Afternoon</td>
<td></td>
</tr>
<tr>
<td>Evening</td>
<td></td>
</tr>
</tbody>
</table>

9. **Ask: Has this been your pattern during the period since __/__/___ (3 months before symptom onset), or has the way you spend your time changed in any way?**

<table>
<thead>
<tr>
<th>Same</th>
<th>Changed</th>
<th>How and when did your daily pattern change?</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

10. **Ask: Please tell me if you have been involved in any of the following activities …**

<table>
<thead>
<tr>
<th></th>
<th>NO</th>
<th>Activity</th>
<th>Where?</th>
<th>When?</th>
<th>With whom?</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td></td>
<td>Watching TV?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Playing cards or games?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Religious services?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Recreation or sports?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Work?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Education?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Library?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Other?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Other?</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

TB Contact Investigation – Interview Questions (page 2 of 3)
11. Ask: Who are your close friends that you spend time with? Are there any others whom you’ve spent time with that you would be concerned about getting exposed to TB?

__________________________________________________________________________

__________________________________________________________________________

__________________________________________________________________________

12. Ask: Since __/__/___ (3 months before symptom onset), have you had any visitors? □ YES □ NO

<table>
<thead>
<tr>
<th>Visitor Name</th>
<th>When Visited</th>
<th>Locating Information</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

13. Ask: Since __/__/___ (3 months before symptom onset), have you had lawyer visits? □ YES □ NO

<table>
<thead>
<tr>
<th>Lawyer Name/Info</th>
<th>When Visited</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

14. Ask: Are there any staff members that you have had close contact with? □ Yes □ No

<table>
<thead>
<tr>
<th>Staff Name</th>
<th>Type of Contact</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

15. Ask: Is there any other information that might help identify anyone else you’ve been in contact with? Is there anyone else who you’re concerned could have become infected with TB by being near you?

__________________________________________________________________________

__________________________________________________________________________

__________________________________________________________________________

16. Ask: Do you have any questions about TB or the plans for your medical care?

__________________________________________________________________________

__________________________________________________________________________

__________________________________________________________________________

TB Contact Investigation – Interview Questions (page 3 of 3)